NZ729856B2 - Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof - Google Patents

Abstract

Disclosed is a binding molecule capable of specifically binding to hemagglutinin (HA) of influenza B virus strains of the B/Yamagata and B/Victoria lineage, and capable of neutralising said influenza B virus strains of the B/Yamagata and/or B/Victoria lineage, wherein the binding molecule does not bind to HA of influenza A viruses, and wherein the binding molecule comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1 (GFSFDEYT), a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2 (INWKGNFM), and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3 (AKDRLESSAMDILEGGTFDI), and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4 (), a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 (GAS), and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:6 (QQYGSSPWT). ind to HA of influenza A viruses, and wherein the binding molecule comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1 (GFSFDEYT), a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2 (INWKGNFM), and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3 (AKDRLESSAMDILEGGTFDI), and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4 (), a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5 (GAS), and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:6 (QQYGSSPWT).

Description

TITLE OF THE INVENTION Human binding molecules capable of binding to and neutralizing influenza B viruses and uses thereof This application is a divisional of New Zealand patent application 628382, which is the national phase entry in New Zealand of PCT international application (published as WO2013/132007), dated 7 March 2013, and claims the benefit of priority to U.S. provisional application no. 61/608414, filed 8 March 2012 and U.S. provisional ation no. 12158525.1, filed 8 March 2012, all of which are incorporated herein by nce.

FIELD OF THE INVENTION The present disclosure relates to medicine. The disclosure in particular relates to human binding molecules, e.g. monoclonal antibodies or antigen-binding fragments thereof, capable of binding to and neutralizing influenza B viruses, in particular neutralizing binding les binding to and neutralizing influenza B viruses from both the B/Yamagata and/or B/Victoria lineage. In addition, the sure relates to the diagnosis, prophylaxis and/or treatment of infections caused by an influenza B virus, in particular of infections caused by influenza B s from the B/Yamagata and B/Victoria es.

BACKGROUND OF THE INVENTION Influenza infection (also referred to as "influenza" or "the flu") is one of the most common diseases known to man causing n three and five million cases of severe illness and between 250,000 and 500,000 deaths every year around the world. Influenza rapidly spreads in seasonal epidemics affecting 5-15% of the population and the burden on health care costs and lost productivity are extensive (World Healthcare Organization (WHO)). There are 3 types of influenza flu virus (types A, B and C) responsible for infectious ogies in humans and s. Currently, the type A and type B s are the agents responsible for the influenza epidemics and pandemics observed in humans.

Current approaches to g with annual influenza epidemics include annual ation, preferably generating heterotypic cross-protection. However, circulating influenza viruses in humans are subject to permanent antigenic changes which e annual tion of the influenza e formulation to ensure the t possible match between the influenza vaccine strains and the circulating nza strains.

Alternatively, antiviral drugs, such as oseltamivir (Tamiflu®) can be effective for prevention and treatment of influenza ion. The number of influenza virus strains showing resistance against antiviral drugs such as oseltamivir is, however, increasing.

An alternative approach is the development of antibody-based lactic or therapeutic means to neutralize various seasonal influenza viruses.

Broadly cross-neutralizing antibodies recognizing epitopes in the conserved stemregion of HA of nza A viruses of phylogenetic group 1 (such as influenza viruses comprising HA of the H1 or H5 subtype) have recently been disclosed (e.g. CR6261, see WO2008/028946), as well as cross-neutralizing antibodies recognizing a highly ved epitope in the stem-region of HA of nza A viruses of phylogenetic group 2, such as influenza viruses comprising HA of the H3 and/or H7 subtypes (e.g. CR8020, ; see WO 30636). More recently, antibodies capable of binding to and neutralizing influenza A viruses of both enetic group 1 and group 2, as well as influenza B viruses were discovered (e.g. CR9114, described in application no.

EP11173953.8).

To date, less attention has been paid to influenza B viruses. This may be due to the fact that – primarily being restricted to humans as host - influenza B viruses lack the large animal reservoirs that are key to the emergence of pandemic influenza A strains.

However, the cumulative impact of annual epidemics during interpandemic periods exceeds that of pandemics and although the morbidity and mortality rates attributable to influenza B are lower than those of e.g. H3N2 viruses, they are higher than those of H1N1 viruses (Thompson (2003), Thompson (2004).

The evolution of influenza B viruses is characterized by co-circulation of antigenically and genetically ct lineages for extended periods of time. Two lineages, represented by the prototype viruses B/Victoria/2/87 (Victoria lineage) and B/Yamagata/16/88 (Yamagata lineage), are currently distinguished (Kanegae (1990), Rota (1990)). B/Yamagata was the major lineage circulating until the 1980s, when B/Victoria lineage viruses appeared. Since then, drift variants of both influenza B lineages have been co-circulating globally, with both lineages concurrently circulating in recent influenza seasons.

Given the fact that influenza B viruses are the major cause of seasonal influenza ics every 2 – 4 years, and in view of the severity of the respiratory illness caused by certain influenza B viruses, as well has the high economic impact of the seasonal epidemics, there is an ongoing need for alternative and effective means for the prevention and treatment influenza B subtypes. There is thus a need for binding les, preferably broadly neutralizing human g molecules, capable of cross-neutralizing influenza B viruses. It an object of the present invention to go some way towards meeting this need and/or to provide the public with a useful choice.

SUMMARY OF THE INVENTION In a first embodiment the present invention provides a binding molecule e of specifically g to hemagglutinin (HA) of influenza B virus strains of the B/Yamagata and oria e, and capable of neutralizing said influenza B virus s of the B/Yamagata and/or B/Victoria lineage, wherein the binding le does not bind to HA of influenza A viruses, wherein the binding le comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 sing the amino acid sequence of SEQ ID NO:6.

In a second embodiment the invention provides an immunoconjugate, comprising at least one binding molecule of the invention and further comprising at least one tag.

In a third embodiment the ion provides a nucleic acid molecule encoding a binding molecule of the invention.

In a fourth embodiment the present invention provides a use of a binding molecule, an immunoconjugate or a nucleic acid molecule of the invention in the manufacture of a medicament.

In a fifth embodiment the invention provides a use of a binding molecule, an immunoconjugate or a nucleic acid molecule of the invention in the manufacture of a medicament for use in the diagnosis, prophylaxis and/or treatment of an influenza infection caused by an influenza B virus.

Also described is a functional variant of a binding molecule of the invention.

In a sixth embodiment the invention provides a pharmaceutical composition comprising a binding molecule or an immunoconjugate of the ion, and a pharmaceutically acceptable carrier or ent.

In a seventh embodiment the invention provides a method of detecting an influenza B virus infection comprising: (a) assaying the level of influenza B virus antigen in a biological sample using a binding molecule or an immunoconjugate of the invention; and (b) comparing the d level of influenza B virus antigen with a control level whereby an increase in the assayed level of influenza B virus antigen ed to the control level of the nza B virus antigen is tive of an influenza B virus infection.

Also described are binding molecules, in particular human binding molecules, capable of ically binding to and neutralizing influenza B virus strains from both the B/Yamagata and B/Victoria lineages. The g molecules do not bind to influenza A virus subtypes.

Also bed are immunoconjugates and/or ceutical compositions comprising the binding molecules, as well as to nucleic acid molecules encoding at least the binding region of the human binding molecules.

The binding molecules, immunoconjugates and/or nucleic acid molecules described herein are le for use as a universal prophylactic, stic and/or treatment agent for influenza B viruses, irrespective of the causative influenza B virus subtype.

DESCRIPTION OF THE FIGURES is a tic epitope map based on competition experiments. Anti-influenza B antibodies identified herein cluster into 4 groups based on binding/competition to influenza B HA. shows the s of an immunofluorescence entry assay designed to analyze the ability of the binding molecules to block receptor binding and internalization of the influenza virus. A. Inhibition of viral entry by immune-fluorescence ut; B.

Infection of MDCK cells with B/Florida/04/2006. shows inhibition of viral egress by the binding molecule described herein. shows the s of scanning EM of influenza B infected cells. shows in vivo tion by CR8033 against lethal nza B infection (B/Florida/04/2006 and B/Malaysia/2506/2004) in mice.

DESCRIPTION OF THE INVENTION Definitions of terms as used in the present disclosure are given below.

The term "included" or "including" as used herein is deemed to be followed by the words "without tion".

As used herein the term "binding molecule" refers to an intact immunoglobulin including monoclonal antibodies, such as chimeric, humanized or human monoclonal antibodies, or to an antigen-binding and/or variable domain comprising fragment of an immunoglobulin that competes with the intact immunoglobulin for specific binding to the binding partner of the immunoglobulin, e.g. HA. Regardless of structure, the antigenbinding nt binds with the same antigen that is recognized by the intact immunoglobulin. An antigen-binding fragment can comprise a peptide or polypeptide comprising an amino acid sequence of at least 2, 5, 10, 15, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100, 125, 150, 175, 200, or 250 contiguous amino acid residues of the amino acid ce of the binding molecule.

The term "binding molecule", as used herein includes all immunoglobulin classes and subclasses known in the art. Depending on the amino acid sequence of the constant domain of their heavy chains, binding les can be divided into the five major classes of intact antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into sses (isotypes), e.g., IgA1, IgA2, IgG1, IgG2, IgG3 and IgG4.

Antigen-binding fragments include, inter alia, Fab, F(ab'), F(ab')2, Fv, dAb, Fd, complementarity determining region (CDR) nts, single-chain antibodies (scFv), bivalent single-chain antibodies, -chain phage antibodies, diabodies, dies, tetrabodies, (poly)peptides that contain at least a fragment of an immunoglobulin that is sufficient to confer specific antigen binding to the peptide, etc. The above fragments may be produced synthetically or by tic or chemical cleavage of intact globulins or they may be genetically engineered by recombinant DNA techniques. The methods of production are well known in the art and are described, for example, in Antibodies: A tory Manual, Edited by: E. Harlow and D, Lane (1988), Cold Spring Harbor tory, Cold Spring Harbor, New York, which is orated herein by reference. A binding molecule or antigen-binding fragment thereof may have one or more binding sites. If there is more than one binding site, the binding sites may be identical to one another or they may be different.

The binding molecule can be a naked or unconjugated binding molecule but can also be part of an immunoconjugate. A naked or ugated g molecule is intended to refer to a binding molecule that is not conjugated, operatively linked or otherwise physically or functionally associated with an effector moiety or tag, such as inter alia a toxic nce, a radioactive substance, a liposome, an enzyme. It will be understood that naked or unconjugated binding molecules do not exclude binding molecules that have been stabilized, multimerized, humanized or in any other way manipulated, other than by the attachment of an effector moiety or tag. Accordingly, all post-translationally modified naked and unconjugated binding molecules are included herewith, including where the modifications are made in the natural binding moleculeproducing cell environment, by a recombinant binding molecule-producing cell, and are introduced by the hand of man after initial binding molecule preparation. Of course, the term naked or unconjugated binding molecule does not exclude the ability of the binding molecule to form functional associations with effector cells and/or molecules after administration to the body, as some of such interactions are necessary in order to exert a ical . The lack of associated effector group or tag is therefore applied in definition to the naked or unconjugated binding molecule in vitro, not in vivo.

As used herein, the term "biological sample" encompasses a variety of sample types, including blood and other liquid samples of biological origin, solid tissue samples such as a biopsy specimen or tissue cultures, or cells derived there from and the progeny thereof. The term also includes samples that have been manipulated in any way after their procurement, such as by ent with reagents, solubilization, or enrichment for n components, such as proteins or polynucleotides. The term encompasses various kinds of al samples ed from any species, and also includes cells in culture, cell supernatants and cell lysates.

The term "complementarity determining regions" (CDR) as used herein means sequences within the variable regions of binding molecules, such as globulins, that usually contribute to a large extent to the antigen binding site which is complementary in shape and charge distribution to the epitope recognized on the antigen.

The CDR regions can be specific for linear epitopes, discontinuous epitopes, or conformational epitopes of proteins or protein nts, either as present on the protein in its native conformation or, in some cases, as present on the proteins as denatured, e.g., by solubilization in SDS. Epitopes may also consist of posttranslational modifications of proteins.

The term "deletion", as used herein, denotes a change in either amino acid or nucleotide sequence in which one or more amino acid or nucleotide es, respectively, are absent as compared to the reference, often the naturally occurring, The term ssion-regulating nucleic acid sequence" as used herein refers to polynucleotide sequences necessary for and/or affecting the expression of an operably linked coding ce in a particular host organism. The expression-regulating nucleic acid sequences, such as inter alia appropriate transcription initiation, ation, promoter, enhancer sequences; repressor or activator sequences; efficient RNA processing signals such as splicing and enylation signals; sequences that stabilize cytoplasmic mRNA; sequences that enhance translation efficiency (e.g., ribosome binding sites); sequences that enhance protein stability; and when desired, sequences that enhance protein secretion, can be any nucleic acid sequence showing activity in the host organism of choice and can be derived from genes encoding proteins, which are either homologous or heterologous to the host organism. The identification and employment of expression-regulating ces is e to the person skilled in the art.

The term ional variant", as used herein, refers to a nucleic acid molecule or binding molecule that comprises a nucleotide and/or amino acid sequence that is altered by one or more nucleotides and/or amino acids compared to the nucleotide and/or amino acid sequences of the reference nucleic acid molecule or binding molecule. A functional variant of a g molecule described herein is e of competing for binding to the binding partner, i.e. the influenza virus, with the reference binding molecule. In other words, the modifications in the amino acid and/or nucleotide sequence of the reference g molecule do not significantly affect or alter the binding characteristics of the g molecule encoded by the nucleotide sequence or containing the amino acid ce, i.e. the binding molecule is still able to recognize and bind its . The functional variant may have conservative sequence modifications including nucleotide and amino acid substitutions, additions and deletions. These modifications can be introduced by standard techniques known in the art, such as site-directed mutagenesis and random PCR-mediated mutagenesis, and may comprise natural as well as non-natural tides and amino acids.

Conservative amino acid substitutions include the ones in which the amino acid residue is replaced with an amino acid residue having similar structural or chemical properties. Families of amino acid residues having similar side chains have been defined in the art. These families e amino acids with basic side chains (e.g., lysine, arginine, histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side chains (e.g., gine, glutamine, , threonine, tyrosine, cysteine, tryptophan), non-polar side chains (e.g., e, alanine, valine, e, isoleucine, proline, phenylalanine, methionine), beta-branched side chains (e.g., threonine, valine, isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan). It will be clear to the skilled artisan that also other classifications of amino acid residue families than the one used above can be employed. rmore, a variant may have non-conservative amino acid tutions, e.g., replacement of an amino acid with an amino acid residue having different structural or chemical properties. Similar minor variations may also include amino acid deletions or insertions, or both. Guidance in determining which amino acid residues may be substituted, inserted, or deleted t abolishing immunological activity may be found using er programs well known in the art.

A mutation in a tide sequence can be a single alteration made at a locus (a point mutation), such as transition or transversion mutations, or alternatively, multiple nucleotides may be ed, deleted or changed at a single locus. In on, one or more alterations may be made at any number of loci within a nucleotide sequence. The mutations may be performed by any suitable method known in the art.

The term "influenza virus subtype" in relation to influenza A viruses refers to influenza A virus variants that are characterized by various combinations of the hemagglutinin (H) and neuramidase (N) viral surface proteins. Influenza A virus subtypes may be referred to by their H number, such as for example "influenza virus comprising HA of the H1 or H3 subtype", or "H1 influenza virus" "H3 influenza virus", or by a combination of an H number and an N number, such as for e "influenza virus subtype H3N2" or "H3N2". The term influenza virus pe" specifically includes all individual influenza virus "strains" within each subtype, which usually result from mutations and show different pathogenic profiles. Such strains may also be referred to as various "isolates" of a viral subtype. Accordingly, as used herein, the terms "strains" and "isolates" may be used interchangeably.

The term "neutralizing" as used herein in relation to the binding molecule bed herein refers to a binding molecule that inhibits an nza virus from replication, in vitro and/or within a subject, regardless of the mechanism by which neutralization is achieved. Thus, neutralization can e.g. be ed by inhibiting the attachment or adhesion of the virus to the cell surface, or by inhibition of the fusion of viral and cellular membranes following attachment of the virus to the target cell, or by inhibiting viral egress from infected cells, and the like.

The term "cross-neutralizing" or "cross-neutralization" as used herein in relation to the binding molecules described herein refers to the y of the binding molecules described herein to neutralize influenza B viruses from both the gata and the oria lineage, and/or different influenza B virus s within these lineages.

The term "host", as used herein, is intended to refer to an organism or a cell into which a vector such as a cloning vector or an expression vector has been introduced. The organism or cell can be prokaryotic or eukaryotic. Preferably, the hosts isolated host cells, e.g. host cells in culture. The term "host cells" merely signifies that the cells are modified for the -expression of the binding molecule bed herein and include B-cells that originally s these binding molecule and which cells have been modified to over-express the binding molecule by alization, amplification, enhancement of expression etc. It should be understood that the term host is intended to refer not only to the particular subject organism or cell but to the progeny of such an organism or cell as well. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent organism or cell, but are still included within the scope of the term "host" as used herein.

The term "human", when applied to binding molecules as defined , refers to les that are either directly derived from a human or based upon a human germ line sequence. When a binding molecule is d from or based on a human sequence and subsequently modified, it is still to be considered human as used throughout the specification. In other words, the term human, when applied to binding molecules is intended to include binding molecules having variable and constant regions derived from human germline immunoglobulin sequences or based on variable or constant regions occurring in a human or human lymphocyte and modified in some form. Thus, the human g molecules may include amino acid residues not encoded by human germline immunoglobulin sequences, comprise substitutions and/or deletions (e.g., mutations introduced by for instance random or site-specific mutagenesis in vitro or by somatic on in vivo). "Based on" as used herein refers to the situation that a nucleic acid sequence may be exactly copied from a template, or with minor mutations, such as by error-prone PCR methods, or synthetically made matching the te exactly or with minor modifications.

The term "insertion", also known as the term "addition", denotes a change in an amino acid or nucleotide sequence resulting in the on of one or more amino acid or nucleotide residues, respectively, as compared to the parent sequence.

The term "isolated", when applied to binding molecules as defined herein, refers to binding molecules that are substantially free of other proteins or polypeptides, particularly free of other binding les having different antigenic specificities, and are also substantially free of other cellular material and/or chemicals. For example, when the binding molecules are recombinantly ed, they are preferably substantially free of culture medium components, and when the binding molecules are produced by chemical synthesis, they are preferably substantially free of al precursors or other chemicals, i.e., they are separated from chemical precursors or other chemicals which are involved in the synthesis of the protein. The term "isolated" when applied to nucleic acid molecules encoding g molecules as defined herein, is intended to refer to c acid molecules in which the nucleotide sequences encoding the binding molecules are free of other tide sequences, particularly nucleotide sequences encoding binding molecules that bind other binding partners. rmore, the term "isolated" refers to nucleic acid molecules that are substantially separated from other cellular components that naturally accompany the native nucleic acid molecule in its natural host, e.g., ribosomes, polymerases, or c sequences with which it is naturally associated.

Moreover, "isolated" nucleic acid molecules, such as cDNA les, can be substantially free of other cellular material, or culture medium when produced by recombinant techniques, or substantially free of chemical precursors or other chemicals when chemically synthesized.

The term lonal antibody" as used herein refers to a preparation of antibody molecules of single specificity. A monoclonal antibody displays a single binding specificity and affinity for a particular epitope. Accordingly, the term "human monoclonal antibody" refers to an antibody displaying a single binding specificity which has variable and constant regions d from or based on human germline globulin sequences or d from completely synthetic sequences. The method of preparing the monoclonal dy is not relevant for the binding specificity.

The term "naturally occurring" as used herein as applied to an object refers to the fact that an object or compound can be found in nature. For example, a polypeptide or polynucleotide sequence that is present in an organism that can be isolated from a source in nature and which has not been intentionally modified by man in the laboratory is naturally ing.

The term "nucleic acid molecule" as used in hereinm refers to a polymeric form of nucleotides and es both sense and anti-sense strands of RNA, cDNA, genomic DNA, and synthetic forms and mixed polymers of the above. A nucleotide refers to a ribonucleotide, deoxynucleotide or a modified form of either type of nucleotide. The term also includes single- and double-stranded forms of DNA. In addition, a polynucleotide may include either or both lly occurring and modified nucleotides linked together by naturally occurring and/or turally occurring nucleotide linkages. The nucleic acid les may be ed chemically or biochemically or may contain non-natural or derivatized nucleotide bases, as will be readily appreciated by those of skill in the art.

Such cations include, for e, labels, ation, substitution of one or more of the naturally occurring nucleotides with an analogue, internucleotide modifications such as uncharged linkages (e.g., methyl phosphonates, phosphotriesters, phosphoramidates, carbamates, etc.), charged linkages (e.g., phosphorothioates, phosphorodithioates, etc.), t moieties (e.g., polypeptides), intercalators (e.g., acridine, psoralen, etc.), chelators, alkylators, and ed linkages (e.g., alpha anomeric nucleic acids, etc.). The above term is also intended to include any topological conformation, including single-stranded, double-stranded, partially duplexed, triplex, hairpinned, circular and ked conformations. Also ed are synthetic molecules that mimic polynucleotides in their ability to bind to a designated sequence via hydrogen bonding and other chemical interactions. Such molecules are known in the art and include, for example, those in which peptide linkages substitute for phosphate linkages in the backbone of the molecule. A reference to a nucleic acid sequence encompasses its complement unless otherwise specified. Thus, a reference to a nucleic acid molecule having a ular sequence should be understood to encompass its complementary strand, with its complementary sequence. The complementary strand is also useful, e.g., for anti-sense therapy, hybridisation probes and PCR primers.

The term "operably linked" refers to two or more c acid sequence elements that are usually physically linked and are in a functional relationship with each other. For instance, a promoter is ly linked to a coding sequence, if the er is able to initiate or regulate the transcription or expression of a coding sequence, in which case the coding sequence should be understood as being "under the control of" the promoter.

By "pharmaceutically acceptable excipient" is meant any inert substance that is combined with an active molecule such as a drug, agent, or binding molecule for preparing an agreeable or convenient dosage form. The "pharmaceutically acceptable excipient" is an excipient that is non-toxic to recipients at the used dosages and concentrations, and is compatible with other ingredients of the formulation comprising the drug, agent or g molecule. Pharmaceutically acceptable excipients are widely applied and known in the art.

The term "specifically binding", as used herein, in reference to the interaction of a binding molecule, e.g. an antibody, and its binding partner, e.g. an antigen, means that the interaction is ent upon the presence of a particular structure, e.g. an antigenic determinant or epitope, on the binding partner. In other words, the dy preferentially binds or recognizes the g partner even when the binding partner is present in a mixture of other molecules or organisms. The binding may be mediated by nt or non-covalent interactions or a combination of both. In yet other words, the term "specifically binding" means immunospecifically g to an antigenic determinant or epitope and not immunospecifically binding to other antigenic determinants or epitopes.

A binding molecule that immunospecifically binds to an antigen may bind to other peptides or polypeptides with lower affinity as determined by, e.g., mmunoassays (RIA), enzyme-linked immunosorbent assays (ELISA), BIACORE, or other assays known in the art. Binding molecules or fragments thereof that immunospecifically bind to an antigen may be reactive with related antigens, carrying the same epitope.

Preferably, binding molecules or fragments f that immunospecifically bind to an antigen do not cross-react with other antigens.

A "substitution", as used herein, denotes the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively.

The term "therapeutically ive amount" refers to an amount of the binding molecule as defined herein that is effective for preventing, ameliorating and/or treating a condition ing from infection with an influenza B virus. Ameloriation as used in herein may refer to the reduction of visible or perceptible disease symptoms, viremia, or any other measurable manifestation of influenza infection.

The term "treatment" refers to therapeutic treatment as well as prophylactic or preventative measures to cure or halt or at least retard disease progress. Those in need of treatment include those already inflicted with a condition resulting from infection with influenza virus as well as those in which infection with influenza virus is to be prevented.

Subjects partially or totally recovered from infection with influenza virus might also be in need of treatment. Prevention encompasses inhibiting or ng the spread of influenza virus or inhibiting or ng the onset, development or ssion of one or more of the symptoms associated with infection with influenza virus.

The term r" denotes a nucleic acid molecule into which a second nucleic acid molecule can be inserted for introduction into a host where it will be replicated, and in some cases expressed. In other words, a vector is capable of transporting a nucleic acid molecule to which it has been linked. Cloning as well as expression s are contemplated by the term "vector", as used herein. Vectors e, but are not limited to, plasmids, cosmids, ial artificial chromosomes (BAC) and yeast artificial chromosomes (YAC) and vectors derived from bacteriophages or plant or animal (including human) viruses. Vectors se an origin of replication recognized by the proposed host and in case of expression vectors, promoter and other regulatory regions recognized by the host. A vector containing a second nucleic acid molecule is introduced into a cell by transformation, transfection, or by making use of viral entry mechanisms.

Certain s are capable of autonomous replication in a host into which they are introduced (e.g., vectors having a bacterial origin of replication can replicate in bacteria).

Other vectors can be integrated into the genome of a host upon uction into the host, and thereby are replicated along with the host genome.

ED DESCRIPTION In a first aspect described are g molecules capable of specifically binding to hemagglutinin (HA) of influenza B virus s of the B/Yamagata and B/Victoria lineage, and capable of neutralizing said nza B virus strains of the B/Yamagata and/or B/Victoria lineage. According to the disclosure, the binding molecules do not bind to HA of nza A viruses. The binding molecules are e of neutralizing influenza B viruses both in vitro and in vivo.

Preferably, the binding molecules are human binding molecules. In a preferred embodiment, the binding molecules are human antibodies, or antigen-binding fragments thereof.

In n embodiments, the g molecules bind to a different epitope as compared to the e of CR9114 (as described in the co-pending application EP11173953.8), sing a heavy chain variable region sing the amino acid sequence of SEQ ID NO: 116, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 117. CR9114 has been shown to be capable of binding to and in vivo neutralizing influenza A viruses of both phylogenetic group 1 and 2, as well as influenza B viruses.

In certain embodiments, the binding molecules bind to the head region of the HA protein of influenza B viruses, in particular to the head region of HA1of influenza B viruses.

In certain embodiments, the binding molecules block the cellular receptor binding of influenza B viruses of the B/Yamagata lineage and/or the B/Victoria lineage.

In certain embodiments, the binding les do not block the cellular receptor binding of influenza viruses of the B/Yamagata lineage and/or the B/Victoria lineage.

In certain embodiments, the g molecules block egress of influenza B viruses, in particular of influenza virus strains of both the B/Victoria and the gata lineage, from infected cells.

In certain embodiments, the isolated binding molecules are e of specifically binding to the hemagglutinin protein (HA) of an influenza B virus and capable of neutralizing influenza B virus strains of both the B/Victoria/2/87 lineage and the B/Yamagata/16/88 lineage, wherein the binding molecules do not bind to the HA protein of influenza A virus subtypes, and comprise a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 71 or a sequence of amino acids having at least or at least about 80 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity thereto.

In certain embodiments, the binding molecules comprise a light chain le region comprising the amino acid sequence set forth in SEQ ID NO: 73, or a sequence of amino acids having at least or at least about 80 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity thereto.

In an embodiment, the binding le comprises a heavy chain variable region sing the amino acid sequence of SEQ ID NO: 71 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 73.

Also described are binding molecules capable of specifically binding to the hemagglutinin n (HA) of an influenza B virus and capable of neutralizing influenza B virus s of both the B/Victoria/2/87 lineage and the B/Yamagata/16/88 lineage, wherein the binding molecules do not bind to the HA protein of influenza A virus subtypes, and wherein the binding molecules comprise a heavy chain CDR1, comprising the sequence of amino acid residues set forth in SEQ ID NO:1; a heavy chain CDR2, comprising the sequence of amino acid residues set forth in SEQ ID NO:2, and a heavy chain CDR3, comprising the ce of amino acid residues set forth in SEQ ID NO:3.

According to the disclosure, CDR regions are ing to Kabat et al. (1991) as described in Sequences of Proteins of Immunological Interest.

In certain embodiments, the g molecules comprise a light chain CDR1, comprising the sequence of amino acid residues set forth in SEQ ID NO: 4, a light chain CDR2, comprising the sequence of amino acid residues set forth in SEQ ID NO: 5, and a light chain CDR3, comprising the sequence of amino acid es set forth in SEQ ID NO: 6.

In certain embodiments, the binding molecule comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 6.

Also described are g molecules that specifically bind to the same epitope on an influenza B virus HA protein as a binding molecule, comprising a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 71 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 73.

In certain embodiments, the binding molecule comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 14, a heavy chain CDR2 sing the amino acid sequence of SEQ ID NO: 15, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 16, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 17, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 18, and a light chain CDR3 comprising the amino acid ce of SEQ ID NO:19.

In certain embodiments, the binding molecule ses a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 26, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 27, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 28, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 29, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:30.

Also described are binding molecules, e of specifically g to the hemagglutinin protein (HA) and capable of neutralizing influenza B virus strains of the B/Victoria lineage, in particular the influenza B virus strain B/Malaysia/2506/2004, when the amino acid on position 168 of HA of the influenza B virus, in particular the influenza B virus strain B/Malaysia/2506/2004, is proline (P), and is not e of lizing influenza B virus strains of the B/Victoria lineage, in particular B/Malaysia/2506/2004, when the amino acid on position 168 of the HA of the influenza B virus, in particular B/Malaysia/2506/2004, is glutamine (Q).

Also described are g molecules, capable of specifically binding to the hemagglutinin protein (HA) and capable of neutralizing influenza B virus strains of the B/Yamagata lineage, in particular the influenza B virus strain B/Florida/04/2006, when the amino acid on position 38 of HA of the influenza B virus, in ular the influenza B virus strain B/Florida/04/200, is lysine (K), and is also capable of neutralizing influenza B virus strains of the B/Yamagata e, in particular B/Florida/04/2006, when the amino acid on position 38 of HA of the influenza B virus, in particular B/Florida/04/2006, is glutamic acid (E).

Also described are binding les that are capable of specifically binding to the hemagglutinin protein (HA) of an influenza B virus and capable of neutralizing influenza B virus strains of both the B/Victoria/2/87 lineage and the B/Yamagata/16/88 lineage, and do not bind to the HA protein of influenza A virus es, and comprise a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 75, or a sequence of amino acids having at least or at least about 80 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity thereto.

In certain embodiments, the binding molecules comprise a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 77, or a sequence of amino acids having at least or at least about 80 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more ce identity thereto.

In certain embodiments, the binding molecules comprise heavy chain variable region comprising the amino acid ce of SEQ ID NO: 75 and a light chain variable region comprising the amino acid ce of SEQ ID NO: 77.

In certain embodiments, the g molecule comprises a heavy chain variable region ting of the amino acid sequence of SEQ ID NO: 78 and a light chain variable region consisting of the amino acid sequence of SEQ ID NO: 79.

Also described are binding molecules capable of specifically binding to the hemagglutinin protein (HA) of an influenza B virus and capable of lizing influenza B virus strains of both the B/Victoria/2/87 lineage and the B/Yamagata/16/88 lineage, wherein the binding molecules do not bind to the HA protein of influenza A virus subtypes, and wherein the binding molecules comprise a heavy chain CDR1, comprising the sequence of amino acid residues set forth in SEQ ID NO: 7; a heavy chain CDR2, sing the sequence of amino acid residues set forth in SEQ ID NO: 8, and a heavy chain CDR3, comprising the sequence of amino acid residues set forth in SEQ ID NO:9.

In certain ments, the binding molecules comprise a light chain CDR1, comprising the sequence of amino acid residues set forth in SEQ ID NO: 10, a light chain CDR2, comprising the sequence of amino acid residues set forth in SEQ ID NO: 11, and a light chain CDR3, comprising the sequence of amino acid residues set forth in SEQ ID NO: 12 or 13.

In n embodiments, the binding le comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a heavy chain CDR2 comprising the amino acid ce of SEQ ID NO: 8, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10, a light chain CDR2 comprising the amino acid ce of SEQ ID NO: 11, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:12.

In certain ments, the binding molecule ses a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 7, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 8, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 9, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 10, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 11, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:13.

Also described are binding molecules that immunospecifically bind to the same epitope on an influenza B virus HA protein as a binding molecule, comprising a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 75 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 77.

In certain embodiments, the binding molecule comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 20, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 21, and a heavy chain CDR3 comprising the amino acid ce of SEQ ID NO: 22, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 23, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 24, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:25.

In certain embodiment, the binding molecule comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 31, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 32, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 33, and a light chain CDR1 sing the amino acid ce of SEQ ID NO: 4, a light chain CDR2 sing the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:34.

Also described are binding molecules, capable of specifically binding to the hemagglutinin protein (HA) and capable of neutralizing influenza B virus strains of the B/Victoria lineage, in particular the influenza B virus strain B/Malaysia/2506/2004, when the amino acid on position 168 of HA of the influenza B virus, in particular the influenza B virus strain B/Malaysia/2506/2004, is proline (P), and also capable of lizing influenza B virus strains of the B/Victoria lineage, in particular ysia/2506/2004, when the amino acid on position 168 of the HA of the influenza B virus, in particular B/Malaysia/2506/2004, is ine (Q).

Also described are binding les, capable of specifically binding to the hemagglutinin protein (HA) and capable of neutralizing influenza B virus strains of the B/Yamagata lineage, in particular the nza B virus strain B/Florida/04/2006, when the amino acid on position 38 of HA of the influenza B virus, in particular the influenza B virus strain B/Florida/04/200, is lysine (K), and not capable of neutralizing influenza B virus strains of the B/Yamagata e, in particular B/Florida/04/2006, when the amino acid on position 38 of HA of the influenza B virus, in ular B/Florida/04/2006, is glutamic acid (E).

Also described are binding molecules, capable of specifically binding to the hemagglutinin protein (HA) of an influenza B virus and capable of neutralizing influenza B virus strains of both the B/Victoria/2/87 lineage and the B/Yamagata/16/88 lineage, wherein the binding molecules do not bind to the HA protein of influenza A virus subtypes, and wherein the binding molecules comprise a heavy chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 113 or a ce of amino acids having at least or at least about 80 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity thereto.

In certain ments, the binding molecules comprise a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 115, or a sequence of amino acids having at least or at least about 80 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more sequence identity thereto.

In an ment, the binding molecule comprises a heavy chain variable region comprising the amino acid ce of SEQ ID NO: 113 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 115.

Also described are binding molecules capable of specifically binding to the hemagglutinin protein (HA) of an influenza B virus and capable of neutralizing influenza B virus strains of both the oria/2/87 lineage and the B/Yamagata/16/88 lineage, wherein the binding molecules do not bind to the HA protein of influenza A virus subtypes, and wherein the binding molecules comprise a heavy chain CDR1, comprising the sequence of amino acid es set forth in SEQ ID NO:54; a heavy chain CDR2, comprising the sequence of amino acid residues set forth in SEQ ID NO:55 and a heavy chain CDR3, comprising the sequence of amino acid residues set forth in SEQ ID NO:56.

In certain embodiments, the g les comprise a light chain CDR1, comprising the sequence of amino acid residues set forth in SEQ ID NO: 57, a light chain CDR2, comprising the sequence of amino acid residues set forth in SEQ ID NO: 5, and a light chain CDR3, comprising the sequence of amino acid residues set forth in SEQ ID NO: 58.

In certain embodiment, the binding molecule comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 54, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 55, and a heavy chain CDR3 sing the amino acid sequence of SEQ ID NO: 56, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 57 a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 sing the amino acid sequence of SEQ ID NO:58.

Also described are binding molecules that immunospecifically bind to the same epitope on an influenza B virus HA protein as a binding molecule, comprising a heavy chain variable sequence comprising the amino acid sequence of SEQ ID NO: 113 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 115.

Influenza B viruses, like influenza A s, infect cells by binding to sialic acid residues on the cell surface of target cells and following transfer into endosomes, by fusing their membranes with the endosomal membranes and ing the genometranscriptase complex into the cell. Both receptor binding and membrane fusion process are mediated by the HA glycoprotein. The HA of both influenza A and B viruses comprises two structurally distinct regions, i.e. a globular head region, which ns a receptor binding site which is responsible for virus attachment to the target cell, and which is involved in the haemagglutination activity of HA, and a stem region, containing a fusion peptide which is ary for membrane fusion between the viral envelope and the endosomal membrane of the cell. The HA protein is a trimer in which each monomer consists of two disulphide - linked glycopolypeptides, HA1 and HA2, that are ed during ion by proteolytic cleavage of a precursor (HA0). Cleavage is necessary for virus infectivity since it is required to prime the HA for ne fusion, to allow conformational change. Activation of the primed le occurs at low pH in endosomes, between pH5 and pH6, and requires extensive changes in HA structure.

In certain embodiments, the binding molecules are e of specifically binding to the HA1 subunit of the HA protein, in particular to the head region of the HA1 subunit.

The binding molecules may be capable of specifically binding to linear or structural and/or conformational epitopes on the HA1 subunit of the HA protein. The HA molecule may be purified from viruses or recombinantly produced and optionally isolated before use. atively, HA may be expressed on the surface of cells.

The binding molecules described herein may be capable of specifically binding to influenza B viruses that are viable, living and/or infective or that are in inactivated/attenuated form. Methods for inactivating/attenuating virus, e.g. nza viruses are well known in the art and include, but are not d to, treatment with formalin, β-propiolactone (BPL), olate, and/or iolet light.

The binding molecules described herein may also be capable of specifically binding to one or more fragments of the influenza B viruses, such as inter alia a preparation of one or more proteins and/or (poly)peptides, derived from subtypes of influenza B viruses or one or more recombinantly produced proteins and/or polypeptides of influenza B viruses. The tide and/or amino acid sequence of proteins of various influenza B strains can be found in the GenBank-database, NCBI Influenza Virus Sequence Database, Influenza Sequence Database (ISD), EMBL-database and/or other databases. It is well within the reach of the skilled person to find such sequences in the respective databases.

In another embodiment the binding molecules described herein are capable of specifically binding to a nt of the above-mentioned proteins and/or polypeptides, wherein the fragment at least comprises an e recognized by the binding les described herein. An "epitope" as used herein is a moiety that is e of g to a binding molecule described herein with sufficiently high affinity to form a detectable n-binding molecule complex.

The binding molecules described herein can be intact immunoglobulin molecules such as monoclonal antibodies, or the binding molecules can be antigen-binding fragments thereof, including, but not limited to, heavy and light chain le regions, Fab, F(ab'), F(ab')2, Fv, dAb, Fd, complementarity determining region (CDR) fragments, single-chain antibodies (scFv), bivalent single-chain antibodies, single-chain phage antibodies, diabodies, triabodies, tetrabodies, and (poly)peptides that contain at least a nt of an immunoglobulin that is sufficient to confer specific antigen binding to influenza virus strains or a fragment thereof. In a preferred embodiment the binding molecules described herein are human monoclonal antibodies, and/or antigen-binding fragments thereof. The binding molecules may also be dies, alphabodies, affibodies, FN3-domain scaffolds and other scaffolds based on domains in (human) repeat proteins, like ins, lins, Darpins, etc, or other scaffolds sing epitope binding sequences.

In certain embodiments, the g molecules are intact antibodies sing complete heavy and light chain variable regions as well as complete heavy and light chain constant regions.

In certain embodiments, the binding molecules have complement-dependent cytotoxic activity (CDC) and/or antibody-dependent cell-mediated cytotoxic (ADCC) activity.

The binding molecules bed herein can be used in non-isolated or isolated form. Furthermore, the binding molecules described herein can be used alone or in a mixture sing at least one g molecule (or variant or fragment thereof) described herein, and one or more other binding molecules that bind to influenza and have influenza virus inhibiting effect. In other words, the g molecules can be used in combination, e.g., as a pharmaceutical composition comprising two or more binding molecules, variants or nts thereof. For example, binding molecules having different, but complementary activities can be combined in a single therapy to achieve a desired prophylactic, therapeutic or diagnostic effect, but alternatively, binding molecules having identical activities can also be combined in a single therapy to achieve a desired prophylactic, therapeutic or diagnostic effect. Optionally, the mixture may also se at least one g molecule described herein and at least one other therapeutic agent.

Preferably, the therapeutic agent such as, e.g., M2 inhibitors (e.g., amantidine, rimantadine) and/or inidase tors (e.g., zanamivir, oseltamivir) is useful in the prophylaxis and/or treatment of an influenza virus infection lly, binding molecule described herein can bind to its binding partners, i.e. an influenza B virus of the gata and/or B/Victoria lineage, and/or fragments thereof, with an affinity constant (Kd-value) that is lower than 0.2x10-4 M, 1.0x10-5 M, 1.0x10-6 M, 1.0x10-7 M, preferably lower than 1.0x10-8 M, more preferably lower than 1.0x10-9 M, more preferably lower than 1.0x10-10 M, even more preferably lower than 1.0x10-11 M, and in particular lower than 1.0x10-12 M. The affinity constants can vary for antibody es. For example, affinity binding for an IgM isotype refers to a binding affinity of at least about 1.0x10-7 M. Affinity constants can for instance be measured using surface plasmon resonance, for example using the BIACORE system (Pharmacia sor AB, Uppsala, Sweden).

The binding molecules described herein exhibit neutralizing activity. Neutralizing activity can for instance be measured as described herein. Alternative assays measuring lizing ty are bed in for instance WHO Manual on Animal Influenza Diagnosis and Surveillance, Geneva: World Health Organisation, 2005, version 2002.5.

Typically, the binding molecules described herein have a neutralizing activity of 50 µg/ml or less, preferably 20 µg/ml or less, more preferably a neutralizing activity of µg/ml or less, even more preferably 5 µg/ml or less, as determined in an in vitro virus neutralization assay (VNA) as described in Example 6. The binding molecules described herein may bind to influenza virus or a fragment f in soluble form such as for ce in a sample or in suspension or may bind to influenza viruses or fragments thereof bound or attached to a r or substrate, e.g., microtiter plates, membranes and beads, etc. Carriers or substrates may be made of glass, c (e.g., polystyrene), polysaccharides, nylon, ellulose, or Teflon, etc. The surface of such supports may be solid or porous and of any convenient shape. Furthermore, the binding molecules may bind to influenza virus in purified/isolated or non-purified/non-isolated form.

As discussed above, the present dislcosure in certain embodiments describes isolated human binding molecules that are able to recognize and bind to an e in the influenza haemagglutinin protein (HA) of influenza B viruses, n said binding les have neutralizing activity against influenza B viruses of both the B/Yamagata and/or B/Victoria lineages, both in vitro and in vivo. According to the disclosure, it has been shown that binding molecules described herein cross-neutralize influenza virus subtypes ing to both phylogenetic es. The d person, based on what has been disclosed herein, can determine whether an antibody indeed cross-reacts with HA proteins from different subtypes and can also determine whether they are able to neutralize nza viruses of different subtypes in vitro and/or in vivo.

Another aspect of the disclosure includes functional variants of the binding molecule as defined above. Molecules are ered to be functional variants of a binding molecule described , if the variant binding molecules are capable of competing for immunospecifically binding to an nza virus or a fragment thereof with the "parental" or "reference" binding molecules. In other words, molecules are considered to be functional variants of a binding molecule described herein when the functional variants are still capable of binding to the same or overlapping epitope of the influenza virus or a fragment thereof. For the sake of this application "parental" and "reference" will be used as synonyms meaning that the information of the reference or parental molecule, or the physical molecule itself may form the basis for the variation.

Functional variants include, but are not limited to, derivatives that are substantially similar in primary structural sequence, including those that have modifications in the Fc receptor or other regions involved with effector functions, and/or which contain e.g. in vitro or in vivo modifications, chemical and/or biochemical, that are not found in the parental binding molecule. Such modifications include inter alia acetylation, acylation, covalent ment of a nucleotide or nucleotide derivative, covalent ment of a lipid or lipid tive, cross-linking, disulfide bond formation, glycosylation, hydroxylation, methylation, ion, pegylation, proteolytic processing, phosphorylation, and the like. Alternatively, functional variants can be binding molecules as defined in the present disclosure comprising an amino acid sequence containing substitutions, insertions, deletions or combinations thereof of one or more amino acids compared to the amino acid sequences of the al binding molecules. Furthermore, functional variants can se truncations of the amino acid sequence at either or both the amino or carboxyl termini. Functional variants described herein may have the same or different, either higher or lower, binding affinities compared to the parental binding molecule but are still capable of binding to the nza virus or a fragment thereof. For ce, functional variants described herein may have sed or decreased binding ties for an influenza virus or a fragment f compared to the parental binding molecules. In certain embodiments, the amino acid sequences of the variable regions, including, but not limited to, framework regions, hypervariable regions, in particular the CDR3 regions, are modified. Generally, the light chain and the heavy chain variable regions comprise three ariable regions, comprising three CDRs, and more conserved s, the so-called ork regions (FRs). The ariable regions comprise amino acid residues from CDRs and amino acid residues from hypervariable loops. Functional variants intended to fall within the scope of the present diusclosure have at least about 80% to about 99%, preferably at least about 70% to about 99%, more preferably at least about 80% to about 99%, even more preferably at least about 90% to about 99%, most preferably at least about 95% to about 99%, in particular at least about 97% to about 99% amino acid sequence identity and/or homology with the parental binding molecules as defined herein. Computer algorithms such as inter alia Gap or Bestfit known to a person skilled in the art can be used to optimally align amino acid sequences to be compared and to define r or identical amino acid residues.

Functional variants can be obtained by altering the parental binding molecules or parts f by general molecular biology methods known in the art including, but not limited to, prone PCR, oligonucleotide-directed mutagenesis, site-directed mutagenesis and heavy and/or light chain shuffling.

In certain embodiments the onal variants bed herein have neutralizing activity against influenza B viruses. The neutralizing activity may either be identical, or be higher or lower compared to the parental binding molecules. As used in this ation, when the term (human) binding molecule is used, this also encompasses functional ts of the ) binding molecule. Assays for verifying if a variant binding molecule has neutralizing activity are well known in the art (see WHO Manual on Animal Influenza Diagnosis and Surveillance, Geneva: World Health Organisation, 2005 version 2002.5).

In certain embodiments, the functional variants are binding molecules comprising a heavy chain variable sequence sing one or more amino acid mutations, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen amino acid mutations, as ed to SEQ ID NO: 71 and/or a light chain variable region comprising one or more amino acid mutations, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen amino acid mutations as compared to SEQ ID NO: 73.

In certain embodiments, the functional variants are binding molecules comprising a heavy chain variable sequence comprising one or more amino acid ons, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen amino acid mutations, as compared to SEQ ID NO: 75 and/or a light chain le region comprising one or more amino acid mutations, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen amino acid mutations as compared to SEQ ID NO: 77.

In certain ments, the functional variants are binding molecules comprising a heavy chain variable sequence comprising one or more amino acid mutations, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen or fifteen amino acid mutations, as compared to SEQ ID NO: 113 and/or a light chain variable region sing one or more amino acid mutations, such as one, two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, en, fourteen or fifteen amino acid mutations as compared to SEQ ID NO: 115.

In certain embodiments, a binding molecule described herein is selected from the group ting of binding les comprising: (a) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid ce of SEQ ID NO: 3, and a light chain CDR1 comprising the amino acid ce of SEQ ID NO: 17, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 18, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 60; (b) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 61, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 62, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 18, and a light chain CDR3 comprising the amino acid ce of SEQ ID NO: 63; (c) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 64, a light chain CDR2 sing the amino acid sequence of SEQ ID NO: 65, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 66; and (d) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 59, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 67, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 68, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 69; (e) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 35, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 36 and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 37, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 38, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 39; (f) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 40, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 41, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 42, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 43, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 44; (g) a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 45, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 46, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 47, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 48, a light chain CDR2 sing the amino acid sequence of SEQ ID NO: 38, and a light chain CDR3 sing the amino acid sequence of SEQ ID NO: 49; and (h) a heavy chain CDR1 sing the amino acid sequence of SEQ ID NO: 45, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 50, and a heavy chain CDR3 comprising the amino acid ce of SEQ ID NO: 47, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, a light chain CDR2 sing the amino acid sequence of SEQ ID NO: 52, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO: 53.

In certain ments, the binding molecule is selected from the group consisting of: a) a binding molecule comprising a heavy chain variable region of SEQ ID NO: 119 and a light chain variable region of SEQ ID NO: 121; b) a binding molecule comprising a heavy chain variable region of SEQ ID NO: 123 and a light chain variable region of SEQ ID NO: 125; c) a binding molecule comprising a heavy chain variable region of SEQ ID NO: 127 and a light chain variable region of SEQ ID NO: 129; d) a binding molecule comprising a heavy chain variable region of SEQ ID NO: 131 and a light chain variable region of SEQ ID NO: 133; e) a binding molecule sing a heavy chain variable region of SEQ ID NO: 77 and a light chain variable region of SEQ ID NO: 79; f) a binding molecule comprising a heavy chain variable region of SEQ ID NO: 101 and a light chain variable region of SEQ ID NO: 103; g) a binding molecule comprising a heavy chain variable region of SEQ ID NO: 105 and a light chain variable region of SEQ ID NO: 107; and h) a binding molecule comprising a heavy chain variable region of SEQ ID NO: 109 and a light chain variable region of SEQ ID NO: 111.

In n embodiments, the binding molecules described herein are for a use as a medicament, and preferably for use in the therapeutic and/or prophylactic treatment of influenza ion caused by influenza B viruses. The influenza virus that causes the influenza infection and that can be treated using the g molecules bed herein may be an influenza B virus of the B/Yamagata and/or B/Victoria lineage.

Also described are ceutical compositions comprising at least one binding molecule described herein, and at least a pharmaceutically acceptable excipient.

Also described is the use of a binding molecule described herein in the preparation of a medicament for the prophylaxis, and/or treatment of an influenza virus infection.

The influenza virus infections that can be prevented and/or treated using the g molecules described herein may occur in small populations, but can also spread around the world in seasonal epidemics or, worse, in global pandemics where millions of individuals are at risk. Also described are binding molecules that can neutralize the ion of influenza strains that cause such al epidemics, as well as potential In yet a further aspect, also described are immunoconjugates, i.e. molecules comprising at least one binding molecule as defined herein and further comprising at least one tag, such as inter alia a detectable moiety/agent. Also contemplated herein are mixtures of conjugates described herein or mixtures of at least one immunoconjugates bed herein and another molecule, such as a therapeutic agent or another binding molecule or immunoconjugate. In further embodiments, the immunoconjugates described herein may comprise more than one tag. These tags can be the same or distinct from each other and can be joined/conjugated non-covalently to the binding molecules. The tag(s) can also be joined/conjugated directly to the human binding molecules through covalent bonding. atively, the tag(s) can be joined/conjugated to the binding molecules by means of one or more linking compounds.

Techniques for conjugating tags to binding les are well known to the skilled artisan.

The tags of the immunoconjugates described herein may be therapeutic agents, but they can also be detectable moieties/agents. Tags le in y and/or tion may be toxins or functional parts f, antibiotics, enzymes, other binding molecules that enhance phagocytosis or immune stimulation. Immunoconjugates comprising a able agent can be used diagnostically to, for example, assess if a subject has been infected with an influenza virus or to monitor the development or progression of an influenza virus infection as part of a clinical g procedure to, e.g., determine the efficacy of a given treatment regimen. However, they may also be used for other detection and/or analytical and/or diagnostic purposes. Detectable moieties/agents include, but are not limited to, enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, ctive materials, positron emitting metals, and non-radioactive paramagnetic metal ions. The tags used to label the binding molecules for detection and/or analytical and/or diagnostic purposes depend on the specific detection/analysis/diagnosis techniques and/or methods used such as inter alia immunohistochemical ng of (tissue) samples, flow cytometric detection, scanning laser cytometric detection, fluorescent immunoassays, enzyme-linked immunosorbent assays s), mmunoassays (RIAs), bioassays (e.g., phagocytosis assays), Western blotting applications, etc. Suitable labels for the detection/analysis/diagnosis techniques and/or methods known in the art are well within the reach of the skilled artisan.

Furthermore, the human g molecules or immunoconjugates described herein can also be attached to solid supports, which are particularly useful for in vitro assays or purification of influenza viruses or fragments thereof. Such solid supports might be porous or nonporous, planar or non-planar. The binding molecules described herein can be fused to marker sequences, such as a peptide to facilitate cation. Examples include, but are not limited to, the hexa-histidine tag, the hemagglutinin (HA) tag, the myc tag or the flag tag. Alternatively, an antibody can be conjugated to a second antibody to form an antibody heteroconjugate. In another aspect the binding molecules described herein may be conjugated/attached to one or more antigens. Preferably, these antigens are antigens which are recognized by the immune system of a subject to which the binding molecule-antigen conjugate is administered. The antigens may be identical, but may also differ from each other. Conjugation methods for attaching the antigens and g molecules are well known in the art and include, but are not limited to, the use of cross-linking agents. The binding molecules described herein will bind to influenza virus HA and the antigens attached to the binding molecules will initiate a powerful T-cell attack on the conjugate, which will eventually lead to the destruction of the influenza virus.

Next to producing immunoconjugates chemically by conjugating, directly or indirectly, via for instance a linker, the conjugates can be produced as fusion proteins comprising the binding molecules bed herein and a suitable tag. Fusion proteins can be ed by s known in the art such as, e.g., recombinantly by constructing nucleic acid molecules comprising nucleotide sequences encoding the binding molecules in frame with tide sequences encoding the suitable tag(s) and then expressing the c acid molecules.

Also described are nucleic acid molecules encoding at least a g molecule, onal variant or immunoconjugate described herein. Such nucleic acid molecules can be used as intermediates for cloning purposes, e.g. in the process of affinity maturation as described above. In a preferred embodiment, the nucleic acid molecules are isolated or purified.

The skilled man will appreciate that onal variants of these nucleic acid molecules are also intended to be a part of the present disclosure. Functional variants are nucleic acid sequences that can be directly translated, using the standard genetic code, to e an amino acid sequence identical to that translated from the parental nucleic acid molecules. ably, the nucleic acid molecules encode g molecules comprising the CDR regions as described above. In a further embodiment the nucleic acid molecules encode binding molecules comprising two, three, four, five or even all six CDR regions of the binding molecules described herein.

In another ment, the c acid molecules encode binding molecules sing a heavy chain comprising the variable heavy chain sequences as described above. In another embodiment the nucleic acid molecules encode binding molecules comprising a light chain comprising the variable light chain sequences as described above. The nucleotide sequences and the amino acid ces of the heavy and light chain le s of the binding molecules described herein are given below.

Also described are vectors, i.e. nucleic acid constructs, comprising one or more nucleic acid molecules described herein. Vectors can be derived from plasmids such as inter alia F, R1, RP1, Col, pBR322, TOL, Ti, etc; s; phages such as lambda, lambdoid, M13, Mu, P1, P22, Qβ, T-even, T-odd, T2, T4, T7, etc; plant viruses. Vectors can be used for cloning and/or for sion of the binding molecules described herein and might even be used for gene therapy purposes. s sing one or more nucleic acid molecules described herein operably linked to one or more expressionregulating nucleic acid molecules are also covered by the present disclosure. The choice of the vector is dependent on the inant procedures followed and the host used. uction of vectors in host cells can be effected by inter alia calcium phosphate transfection, virus infection, DEAE-dextran mediated transfection, lipofectamin transfection or electroporation. Vectors may be autonomously replicating or may replicate together with the chromosome into which they have been integrated. Preferably, the vectors contain one or more selection markers. The choice of the markers may depend on the host cells of choice, although this is not critical to the invention as is well known to persons skilled in the art. They include, but are not limited to, cin, neomycin, puromycin, hygromycin, zeocin, thymidine kinase gene from Herpes simplex virus (HSV-TK), dihydrofolate reductase gene from mouse (dhfr). s comprising one or more nucleic acid molecules encoding the human binding molecules as described above operably linked to one or more nucleic acid molecules encoding proteins or peptides that can be used to isolate the human binding molecules are also covered by the present disclosure. These proteins or peptides include, but are not limited to, glutathione-S- transferase, maltose binding n, metal-binding polyhistidine, green fluorescent protein, luciferase and beta-galactosidase.

Hosts containing one or more copies of the vectors mentioned above are an additional aspect of the t disclosure. Preferably, the hosts are host cells. Host cells include, but are not d to, cells of ian, plant, , fungal or bacterial origin. Bacterial cells include, but are not limited to, cells from Gram-positive bacteria or Gram-negative bacteria such as several species of the genera Escherichia, such as E. coli, and Pseudomonas. In the group of fungal cells preferably yeast cells are used. Expression in yeast can be achieved by using yeast strains such as inter alia Pichia pastoris, Saccharomyces cerevisiae and Hansenula polymorpha. rmore, insect cells such as cells from Drosophila and Sf9 can be used as host cells. Besides that, the host cells can be plant cells such as inter alia cells from crop plants such as forestry plants, or cells from plants providing food and raw materials such as cereal plants, or medicinal plants, or cells from ornamentals, or cells from flower bulb crops. Transformed genic) plants or plant cells are produced by known methods, for example, Agrobacterium-mediated gene transfer, transformation of leaf discs, protoplast transformation by polyethylene glycolinduced DNA transfer, electroporation, sonication, microinjection or bolistic gene transfer. Additionally, a suitable expression system can be a baculovirus system.

Expression systems using mammalian cells, such as Chinese Hamster Ovary (CHO) cells, COS cells, BHK cells, NSO cells or Bowes melanoma cells are preferred in the t disclosure. Mammalian cells provide expressed proteins with posttranslational modifications that are most similar to natural les of mammalian origin. Since the present disclosure deals with molecules that may have to be administered to humans, a tely human expression system would be particularly preferred. Therefore, even more preferably, the host cells are human cells. Examples of human cells are inter alia HeLa, 911, AT1080, A549, 293 and HEK293T cells. In preferred embodiments, the human producer cells comprise at least a functional part of a nucleic acid sequence ng an irus E1 region in expressible format. In even more preferred embodiments, said host cells are derived from a human retina and immortalized with nucleic acids comprising adenoviral E1 sequences, such as 911 cells or the cell line deposited at the European Collection of Cell Cultures ), CAMR, Salisbury, Wiltshire SP4 OJG, Great Britain on 29 February 1996 under number 96022940 and ed under the trademark PER.C6® (PER.C6 is a registered trademark of Crucell Holland B.V.). For the purposes of this application "PER.C6 cells" refers to cells deposited under number 40 or ors, passages up-stream or downstream as well as descendants from ancestors of deposited cells, as well as derivatives of any of the foregoing. Production of recombinant proteins in host cells can be performed according to methods well known in the art. The use of the cells marketed under the trademark PER.C6® as a production platform for proteins of st has been described in WO 00/63403 the disclosure of which is incorporated herein by reference in its entirety.

A method of producing a binding molecule described herein is an additional aspect of the disclosure. The method ses the steps of a) culturing a host described herein under conditions conducive to the expression of the binding molecule, and b) optionally, recovering the sed binding molecule. The expressed binding molecules can be red from the cell free t, but preferably they are recovered from the culture medium. The above method of producing can also be used to make functional variants of the binding molecules and/or immunoconjugates bed herein. s to recover proteins, such as binding molecules, from cell free ts or culture medium are well known to the man skilled in the art. Binding molecules, functional variants and/or immunoconjugates obtainable by the above-described method are also a part of the present disclosure.

Alternatively, next to the expression in hosts, such as host cells, the binding molecules and immunoconjugates described herein can be produced synthetically by conventional e synthesizers or in cell-free translation systems using RNA nucleic acid derived from DNA molecules described herein. Binding molecules and immunoconjugates as obtainable by the above described synthetic production methods or cell-free translation systems are also a part of the present disclosure.

In yet another embodiment, g molecules bed herein can also be produced in transgenic, non-human, mammals such as inter alia rabbits, goats or cows, and secreted into for instance the milk thereof.

In yet another alternative embodiment, binding molecules described herein may be generated by transgenic non-human mammals, such as for instance transgenic mice or s that express human immunoglobulin genes. Preferably, the transgenic non-human mammals have a genome comprising a human heavy chain transgene and a human light chain transgene encoding all or a portion of the human binding les as described above. The transgenic non-human mammals can be immunized with a purified or enriched preparation of influenza virus or a nt thereof. Protocols for immunizing non-human mammals are well established in the art. See Using Antibodies: A Laboratory Manual, Edited by: E. Harlow, D. Lane (1998), Cold Spring Harbor Laboratory, Cold Spring Harbor, New York and Current Protocols in Immunology, Edited by: J.E. Coligan, A.M. eek, D.H. Margulies, E.M. Shevach, W. Strober (2001), John Wiley & Sons Inc., New York, the disclosures of which are incorporated herein by reference.

Immunization protocols often e le immunizations, either with or without adjuvants such as Freund's te adjuvant and Freund's lete adjuvant, but may also include naked DNA immunizations. In another embodiment, the human binding molecules are produced by B-cells, plasma and/or memory cells derived from the transgenic animals. In yet another ment, the human binding molecules are produced by hybridomas, which are prepared by fusion of B-cells obtained from the above-described transgenic non-human mammals to immortalized cells. B-cells, plasma cells and hybridomas as obtainable from the above-described transgenic non-human s and human binding molecules as obtainable from the described transgenic non-human mammals, B-cells, plasma and/or memory cells and hybridomas are also a part of the present disclosure.

Also described are compositions comprising at least a binding molecule, preferably a human monoclonal antibody, described , at least a functional variant thereof, at least an immunoconjugate described herein and/or a combination thereof. In addition to that, the compositions may se inter alia stabilizing molecules, such as albumin or polyethylene glycol, or salts. Preferably, the salts used are salts that retain the desired biological activity of the binding les and do not impart any undesired toxicological effects. If necessary, the human binding molecules described herein may be coated in or on a material to t them from the action of acids or other natural or nonnatural conditions that may inactivate the binding molecules.

Also bed are compositions comprising at least a nucleic acid molecule as defined herein. The compositions may comprise aqueous solutions such as aqueous solutions containing salts (e.g., NaCl or salts as described above), detergents (e.g., SDS) and/or other suitable components.

Also described are pharmaceutical compositions sing at least a binding molecule, such as a human monoclonal antibody, described herein (or functional nt or t thereof), at least an conjugate described herein, at least a composition described herein, or combinations thereof. The ceutical composition described herein further comprises at least one pharmaceutically acceptable excipient.

Pharmaceutically acceptable ents are well known to the skilled person. The pharmaceutical composition described herein may further comprise at least one other therapeutic agent. Suitable agents are also well known to the skilled artisan.

In certain embodiments the pharmaceutical composition described herein comprises at least one additional binding molecule, i.e. the pharmaceutical composition can be a cocktail or mixture of binding molecules. The pharmaceutical composition may comprise at least two binding molecules described herein, or at least one g molecule described herein and at least one r influenza virus binding and/or neutralizing le, such as another antibody directed t the HA protein or against other antigenic structures present on influenza viruses, such as M2, and/or a binding molecules neutralizing one or more other pathogens. In another embodiment the additional binding molecule may be formulated for simultaneous separate or sequential administration.

In certain embodiments, the binding molecules exhibit synergistic neutralizing activity, when used in combination. As used herein, the term "synergistic" means that the combined effects of the binding molecules when used in combination are greater than their additive s when used individually. The synergistically acting binding molecules may bind to ent structures on the same or distinct fragments of influenza virus. A way of calculating synergy is by means of the combination index. The concept of the combination index (CI) has been described by Chou and Talalay . The compositions may e.g. comprise one binding le having neutralizing activity and one non-neutralizing binding molecule. The non-neutralizing and neutralizing binding molecules may also act synergistically in neutralizing influenza virus.

In certain ments, the pharmaceutical ition may comprise at least one binding molecule described herein and at least one further binding molecule, preferably a further influenza virus neutralizing binding molecule. The binding molecules in the pharmaceutical composition preferably are capable of reacting with influenza viruses of different subtypes. The binding molecules may be of high affinity and have a broad specificity. Preferably, both binding molecules are cross-neutralizing molecules in that they each neutralize influenza viruses of ent subtypes. In on, preferably they neutralize as many strains of each of the different influenza virus subtypes as possible.

In certain embodiments, the pharmaceutical composition comprises at least one other lactic and/or therapeutic agent. Preferably, said further therapeutic and/or prophylactic agents are agents capable of preventing and/or treating an influenza virus infection and/or a condition resulting from such an ion. Therapeutic and/or prophylactic agents include, but are not limited to, anti-viral agents. Such agents can be binding les, small les, organic or inorganic compounds, enzymes, polynucleotide sequences, anti-viral peptides, etc. Other agents that are currently used to treat patients infected with influenza viruses are M2 inhibitors (e.g., amantidine, rimantadine) and/or neuraminidase inhibitors (e.g., vir, oseltamivir). These can be used in ation with the binding molecules described herein. "In combination" herein means simultaneously, as separate formulations, or as one single combined formulation, or ing to a sequential administration regimen as separate formulations, in any order. Agents capable of preventing and/or ng an infection with influenza virus and/or a condition resulting from such an infection that are in the experimental phase might also be used as other therapeutic and/or prophylactic agents useful herein.

The binding molecules or pharmaceutical compositions described herein can be tested in suitable animal model systems prior to use in humans. Such animal model systems include, but are not d to, mouse, ferret and monkey.

Typically, pharmaceutical compositions must be sterile and stable under the conditions of manufacture and storage. The binding molecules, immunoconjugates, or compositions described herein can be in powder form for reconstitution in the appropriate pharmaceutically acceptable excipient before or at the time of delivery. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze-drying (lyophilization) that yield a powder of the active ingredient plus any additional desired ingredient from a previously sterilefiltered solution thereof.

Alternatively, the binding molecules, immunoconjugates, or compositions described herein can be in solution and the appropriate pharmaceutically acceptable excipient can be added and/or mixed before or at the time of delivery to provide a unit dosage injectable form. Preferably, the pharmaceutically able excipient used herein is suitable to high drug concentration, can maintain proper ty and, if necessary, can delay absorption.

The choice of the optimal route of administration of the pharmaceutical compositions will be influenced by several factors including the physicochemical ties of the active molecules within the compositions, the urgency of the clinical situation and the relationship of the plasma concentrations of the active molecules to the desired eutic effect. For instance, if ary, the binding molecules bed herein can be prepared with carriers that will protect them against rapid e, such as a controlled release formulation, including implants, transdermal patches, and ncapsulated delivery systems. Biodegradable, biocompatible polymers can inter alia be used, such as ethylene vinyl acetate, polyanhydrides, polyglycolic acid, collagen, polyorthoesters, and ctic acid. Furthermore, it may be ary to coat the binding molecules with, or co-administer the binding molecules with, a material or compound that prevents the inactivation of the human binding molecules. For example, the g les may be administered to a subject in an appropriate carrier, for example, liposomes or a diluent.

The routes of stration can be divided into two main categories, oral and eral administration. The preferred administration route is intravenous or by inhalation.

Oral dosage forms can be formulated inter alia as tablets, troches, lozenges, aqueous or oily suspensions, dispersible powders or granules, emulsions, hard capsules, soft gelatin capsules, syrups or elixirs, pills, s, liquids, gels, or slurries. These formulations can contain pharmaceutically ents including, but not limited to, inert diluents, granulating and egrating agents, binding agents, ating agents, preservatives, colouring, flavouring or sweetening agents, vegetable or mineral oils, wetting agents, and thickening agents.

The pharmaceutical compositions described herein can also be ated for parenteral administration. Formulations for parenteral administration can be inter alia in the form of aqueous or non-aqueous isotonic sterile non-toxic injection or infusion solutions or suspensions. The ons or suspensions may comprise agents that are nontoxic to recipients at the dosages and concentrations employed such as 1,3-butanediol, Ringer’s solution, Hank’s solution, isotonic sodium chloride solution, oils, fatty acids, local anaesthetic agents, preservatives, buffers, viscosity or solubility increasing agents, water-soluble antioxidants, luble antioxidants and metal chelating agents.

In a further aspect, the binding molecules such as human monoclonal antibodies (functional fragments and variants thereof), immunoconjugates, compositions, or pharmaceutical compositions described herein can be used as a medicament or diagnostic agent. So, methods of diagnosis, treatment and/or prevention of an influenza virus infection using the g molecules, immunoconjugates, compositions, or pharmaceutical itions described herein are another aspect of the present disclosure. The above-mentioned molecules can inter alia be used in the diagnosis, laxis, treatment, or combination thereof, of an influenza virus infection caused by an influenza B virus. They are le for treatment of yet ted patients suffering from an influenza virus infection and patients who have been or are treated for an influenza virus infection.

The above-mentioned molecules or itions may be employed in ction with other molecules useful in diagnosis, prophylaxis and/or treatment. They can be used in vitro, ex vivo or in vivo. For instance, the binding molecules such as human monoclonal antibodies (or functional ts thereof), conjugates, compositions or pharmaceutical compositions described herein can be co-administered with a vaccine against influenza virus (if available). Alternatively, the vaccine may also be administered before or after administration of the molecules described herein. Instead of a vaccine, anti-viral agents can also be employed in ction with the binding les described herein. Suitable anti-viral agents are mentioned above.

The molecules are lly formulated in the compositions and pharmaceutical compositions described herein in a therapeutically or diagnostically effective amount.

Alternatively, they may be formulated and administered separately. For instance the other molecules such as the anti-viral agents may be applied systemically, while the binding les described herein may be applied intravenously.

Treatment may be targeted at patient groups that are susceptible to nza infection. Such t groups include, but are not limited to e.g., the elderly (e.g. ≥ 50 years old, ≥ 60 years old, and preferably ≥ 65 years old), the young (e.g. ≤ 5 years old, ≤ 1 year old), hospitalized patients and already ed ts who have been treated with an antiviral compound but have shown an inadequate antiviral response.

Dosage regimens can be adjusted to provide the optimum d response (e.g., a therapeutic response). A suitable dosage range may for instance be 0.01-100 mg/kg body weight, preferably 0.1-50 mg/kg body weight, preferably 0.01-15 mg/kg body weight. Furthermore, for example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. The molecules and compositions described herein are preferably sterile. Methods to render these molecules and compositions sterile are well known in the art. The other molecules useful in diagnosis, prophylaxis and/or treatment can be administered in a similar dosage regimen as proposed for the binding les described herein. If the other molecules are administered separately, they may be administered to a t prior to (e.g., 2 min, 5 min, 10 min, 15 min, 30 min, 45 min, 60 min, 2 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, 14 hrs, 16 hrs, 18 hrs, 20 hrs, 22 hrs, 24 hrs, 2 days, 3 days, 4 days, 5 days, 7 days, 2 weeks, 4 weeks or 6 weeks before), concomitantly with, or subsequent to (e.g., 2 min, 5 min, 10 min, 15 min, 30 min, 45 min, 60 min, 2 hrs, 4 hrs, 6 hrs, 8 hrs, 10 hrs, 12 hrs, 14 hrs, 16 hrs, 18 hrs, 20 hrs, 22 hrs, 24 hrs, 2 days, 3 days, 4 days, 5 days, 7 days, 2 weeks, 4 weeks or 6 weeks after) the administration of one or more of the human g molecules or pharmaceutical compositions described herein. The exact dosing regimen is usually sorted out during clinical trials in human ts.

Human binding molecules and pharmaceutical compositions comprising the human binding molecules are particularly useful, and often preferred, when to be administered to human beings as in vivo therapeutic agents, since recipient immune response to the administered antibody will often be substantially less than that occasioned by stration of a monoclonal murine, chimeric or humanized binding molecule.

Also described is the use of the binding molecules such as neutralizing human monoclonal antibodies (functional fragments and variants thereof), immunoconjugates, nucleic acid molecules, compositions or pharmaceutical compositions described herein in the preparation of a medicament for the diagnosis, prophylaxis, treatment, or combination thereof, of an influenza virus infection, in particular an influenza virus infection caused by influenza B viruses.

Next to that, kits comprising at least a binding molecule such as a neutralizing human monoclonal dy (functional nts and variants thereof), at least an immunoconjugate, at least a nucleic acid molecule, at least a composition, at least a pharmaceutical composition, at least a vector, at least a host described herein or a combination thereof are also an aspect of the present disclosure. Optionally, the abovedescribed components of the kits bed herein are packed in le containers and labelled for diagnosis, prophylaxis and/or treatment of the indicated conditions. The above-mentioned ents may be stored in unit or multi-dose containers as an aqueous, preferably sterile, solution or as a lyophilised, preferably sterile, ation for reconstitution. The ners may be formed from a variety of materials such as glass or plastic and may have a e access port (for example, the container may be an enous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). The kit may further comprise more containers comprising a pharmaceutically able buffer. It may further e other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, s, syringes, culture medium for one or more of the suitable hosts and, possibly, even at least one other therapeutic, prophylactic or diagnostic agent. Associated with the kits can be instructions customarily included in commercial packages of therapeutic, prophylactic or diagnostic products, that contain ation about for example the indications, usage, dosage, manufacture, administration, contra-indications and/or gs concerning the use of such therapeutic, prophylactic or diagnostic products.

The binding molecules described herein can also be advantageously used as a diagnostic agent in an in vitro method for the detection of nza virus. Thus also described is a method of detecting influenza B subtype influenza virus in a sample, wherein the method comprises the steps of (a) assaying the level of influenza B virus antigen in a biological sample using a binding molecule described herein and/or an immunoconjugate described ; and (b) comparing the assayed level of influenza B virus antigen with a control level whereby an increase in the d level of influenza B virus n compared to the control level of the influenza B virus antigen is indicative of an influenza B virus infection.

The ical sample may be a biological sample including, but not limited to blood, serum, stool, sputum, nasopharyngal aspirates, bronchial s, urine, tissue or other biological material from (potentially) infected subjects, or a non-biological sample such as water, drink, etc. The (potentially) infected subjects may be human subjects, but also s that are suspected as carriers of influenza virus might be tested for the presence of the virus using the human binding molecules or immunoconjugates described herein. The sample may first be manipulated to make it more suitable for the method of detection. Manipulation means inter alia ng the sample suspected to contain and/or containing the virus in such a way that the virus will disintegrate into antigenic components such as proteins, (poly)peptides or other antigenic fragments. Preferably, the human binding molecules or immunoconjugates bed herein are contacted with the sample under conditions which allow the formation of an immunological complex between the human g molecules and the virus or antigenic ents thereof that may be present in the sample. The formation of an immunological complex, if any, indicating the presence of the virus in the sample, is then detected and measured by suitable means. Such methods include, inter alia, homogeneous and heterogeneous binding immunoassays, such as radio-immunoassays (RIA), ELISA, immunofluorescence, immunohistochemistry, FACS, BIACORE and Western blot analyses.

Preferred assay techniques, especially for large-scale clinical screening of patient sera and blood and blood-derived products are ELISA and Western blot techniques.

ELISA tests are particularly preferred. For use as reagents in these assays, the binding molecules or immunoconjugates bed herein are conveniently bonded to the inside surface of microtiter wells. The binding molecules or immunoconjugates bed herein may be directly bonded to the microtiter well. However, maximum binding of the binding molecules or immunoconjugates described herein to the wells might be lished by eating the wells with polylysine prior to the addition of the binding les or immunoconjugates described herein. Furthermore, the g molecules or immunoconjugates described herein may be covalently ed by known means to the wells. Generally, the binding molecules or immunoconjugates are used in a tration between 0.01 to 100 μg/ml for coating, although higher as well as lower amounts may also be used. Samples are then added to the wells coated with the binding molecules or immunoconjugates described herein.

Also described are methods of ng or preventing an influenza B virus infection in a subject, comprising administering to the subject a therapeutically or prophylactically effective amount of the binding molecules, immunoconjugates and/or pharmaceutical itions described herein. In certain embodiments, the subject is a mammal, preferably a human.

Furthermore, binding molecules described herein can be used to identify specific binding structures of nza virus. The binding structures can be epitopes on proteins and/or polypeptides. They can be linear, but also structural and/or conformational. In one embodiment, the binding structures can be ed by means of PEPSCAN analysis (see inter alia WO 84/03564, WO 72, Slootstra et al., 1996). Alternatively, a random e library comprising peptides from a protein of influenza virus can be screened for peptides capable of binding to the binding molecules described herein.

The invention is further illustrated in the following examples and figures. The examples are not intended to limit the scope of the invention in any way.

EXAMPLES EXAMPLE 1 Construction of scFv phage display libraries using RNA extracted from memory B cells.

Peripheral blood was collected from normal healthy donors by venapuncture in EDTA anti-coagulation sample tubes. Single chain Fv (scFv) phage display libraries were obtained as described in The final library was checked for insert frequency with a colony PCR using a primer set flanking the inserted VH-VL regions (100-150 single colonies). Typically, more than 95% of the colonies showed a correct length insert (see Table 1). The colony PCR ts were used for subsequent DNA sequence analysis to check sequence variation and to assess the percentage of colonies showing a complete ORF. This was typically above 70% (see Table 1). The frequency of ons in the V genes was also analysed.

About 95% of the sequences were not in germline configuration indicative of a maturation process and consistent with the memory phenotype of the B cells used as an RNA source for the library.

A two-round PCR ication approach was applied, using the primer sets shown in respective donor repertoire.

First round amplification on the respective cDNA d seven, six and nine products of about 650 base pairs for VH, Vkappa and Vlambda regions, respectively. For IgM memory B cell VH region amplification, the OCM constant primer (IgM nt heavy chain specific) was used in combination with OH1 to OH7. The l cycling program for first round amplifications was: 2 min 96°C (denaturation step), 35 cycles of sec 96°C/ 30 sec 60°C/ 50 sec 72°C, 10 min 72°C final elongation and 6°C refrigeration. The products were loaded on and isolated from a 1% agarose gel using gelextraction columns (Macherey-Nagel, MN) and eluted in 50 μl 5 mM Tris-HCl pH 8.0.

Ten percent of first round ts (5 μl) were subjected to second round amplification.

These primers were extended with restriction sites enabling the directional cloning of the respective VL and VH regions into phage display vector PDV-C06. The PCR program for second round amplifications was as follows: 2 min 96°C (denaturation step), 30 cycles of 30 sec 96°C/ 30 sec 60°C/ 50 sec 72°C, 10 min 72°C final elongation and 6°C refrigeration. The second round products (~350 base pairs) were first loaded on gel and extracted from the agarose as above. Then the fragments were pooled according to natural occurrence of J segments found in immunoglobulin gene products, resulting in seven, six and nine pools for respectively the VH, Vkappa and Vlambda variable regions as shown in Table 1 and 2.

To obtain a normalized distribution of immunoglobulin sequences in the immune library the six Vkappa and nine Vlambda light chain pools were mixed according to the percentages ned in Table 1. This single final VL pool (5 μg) was digested with SalI and NotI restriction enzymes, loaded on and isolated from a 1.5% agarose gel (~350 base pairs) using MN-extraction columns and ligated in SalI-NotI cut PDV-C06 vector (~5000 base pairs) as follows: 500ng PDV-C06 vector, 70 ng VL insert, 5 μl 10X ligation buffer (NEB), 2.5 T4 DNA Ligase (400 U/μl) (NEB), and ultrapure water was added up to a total volume of 50µl (vector to insert ratio was 1:2). on was performed overnight in a water bath of 16°C. Next, the volume was doubled with water, extracted with an equal volume of phenol-chloroform-isoamylalcohol (75:24:1) (Invitrogen) followed by form (Merck) tion and precipitated with 1 μl Pellet Paint (Novogen), 10 μl sodium acetate (3 M pH 5.0) and 100 μl isopropanol for 2 hrs at -20°C.

The ed sample was subsequently centrifuged at xg for 30 min at 4°C. The obtained precipitate was washed with 70% ethanol and centrifuged for 10 min at .000xg at room temperature. Ethanol was d and the pellet was air dried for several min and then dissolved in 50 μl buffer containing 10 mM Tris-HCl, pH 8.0. 2 μl ligation mixture was used for the transformation of 40 μl TG-1 electro-competent cells (Agilent) in a chilled 0.1 cm electroporation e (Biorad) using a Genepulser II apparatus (Biorad) set at 1.7 kV, 200 Ohm, 25 μF (time constant ~4,5 msec). Directly after pulse, the bacteria were d from the cuvette with 750 μl SOC medium (Invitrogen) containing 5% (w/v) glucose (Sigma) at 37°C and transferred to a 15 ml round bottom culture tube. Another 750 μl SOC/glucose was used to flush residual bacteria from the cuvette and was added to the culture tube. Bacteria were recovered by culturing for exactly one hr at 37°C in a shaker incubator at 220 rpm. The transformed bacteria were plated over large 240 mm square petridishes (NUNC) containing 200 ml 2TY agar (16 g/l bacto-tryptone, 10 g/l bacto-yeast extract, 5 g/l NaCl, 15 g/l agar, pH 7.0) supplemented with 50 μg/ml llin and 5% (w/v) glucose (Sigma). A 1 to 1000 and a 1 to 10.000 dilution were plated for counting purposes on 15 cm petridishes containing the same medium. This transformation ure was repeated sequentially twenty times and the complete library was plated over a total of ten large square petridishes and grown overnight in a 37°C e stove. Typically, around 1x107 cfu were obtained using the above protocol. The intermediate VL light chain library was harvested from the plates by mildly scraping the bacteria into 12 ml 2TY medium per plate. The cell mass was determined by OD600 measurement and two times 500 OD of bacteria was used for maxi plasmid DNA preparation using two maxiprep columns (MN) according to cturer's ctions.

Analogous to the VL variable regions, the second round VH-JH products were first mixed together to obtain the normal J segment usage distribution (see Table 2), resulting in 7 VH subpools called PH1 to PH7. The pools were mixed to acquire a normalized sequence distribution using the percentages ed in Table 2, obtaining one VH fraction that was digested with SfiI and XhoI restriction enzymes and ligated in SfiI-XhoI cut PDV-VL intermediate library obtained as described above. The ligation setup , purification method, subsequent transformation of TG1 and harvest of bacteria was exactly as described for the VL intermediate library (see above), with the exception of the number of 240 mm plates used. For the final library twenty plates were used, resulting in approximately 2x107 cfu. The final library was d for insert frequency with a colony PCR using a primer set ng the inserted VH-VL s (100-150 single colonies). Typically, more than 95% of the colonies showed a t length insert (see Table 3). The colony PCR products were used for subsequent DNA sequence analysis to check sequence variation and to assess the percentage of colonies showing a complete ORF. This was lly above 70% (see Table 3). The frequency of ons in the V genes was also analysed. About 95% of the sequences were not in germline configuration indicative of a maturation process and consistent with the memory phenotype of the B cells used as an RNA source for the library. Finally, the library was d and amplified by using CT helper phages (see WO 02/103012) and was used for phage antibody selection by panning methods as described below.

EXAMPLE 2 Selection of phages carrying single chain Fv fragments against Influenza B.

Selection was performed using the dy phage display ies against recombinant hemagglutinin (HA) of influenza B (B/Ohio/01/2005, B/Florida/04/2006 and B/Brisbane/60/2008). HA antigens were diluted in PBS (5.0 μg/ml), added to MaxiSorpTM Nunc-Immuno Tubes (Nunc), 2 ml per tube, and incubated overnight at 4°C on a rotating wheel. The tubes were d and washed three times with block buffer (2% non-fat dry milk (ELK) in PBS). Subsequently, the tubes were filled completely with block buffer and incubated for 1-2 hrs at room temperature. Aliquots of the phage display library (350-500 µl, amplified using CT helper phage (see WO 02/103012)) were blocked in blocking buffer (optionally: supplemented with 10% nonheat inactivated fetal bovine serum and 2% mouse serum) for 1-2 hrs at room temperature. The blocked phage library was added to the immunotubes, incubated for 2 hrs at room temperature, and washed with wash buffer (0.05% (v/v) Tween-20 in PBS) to remove unbound . Bound phages were eluted from the respective antigen by incubation with 1 ml of 100 mM triethylamine (TEA) for 10 min at room temperature.

Subsequently, the eluted phages were mixed with 0.5 ml of 1 M Tris-HCl pH 7.5 to lize the pH. This mixture was used to infect 5 ml of an XL1-Blue E.coli culture that had been grown at 37°C to an OD 600 nm of approximately 0.3. The phages were allowed to infect the XL1-Blue bacteria for 30 min at 37°C. Then, the mixture was centrifuged for 10 min at 3000xg at room temperature and the bacterial pellet was resuspended in 0.5 ml 2-trypton yeast extract (2TY) medium. The ed bacterial suspension was divided over two 2TY agar plates supplemented with tetracycline, ampicillin and glucose. After incubation overnight of the plates at 37ºC, the colonies were scraped from the plates and used to prepare an enriched phage library, essentially as described by De Kruif et al. (1995a) and in WO 02/103012. Briefly, scraped bacteria were used to inoculate 2TY medium containing ampicillin, tetracycline and e and grown at a temperature of 37ºC to an OD 600 nm of ~0.3. CT helper phages were added and allowed to infect the bacteria after which the medium was changed to 2TY containing ampicillin, ycline and kanamycin. tion was continued overnight at 30ºC. The next day, the bacteria were removed from the 2TY medium by centrifugation after which the phages in the medium were itated using polyethylene glycol (PEG) 6000/NaCl. Finally, the phages were dissolved in 2 ml of PBS with 1% bovine serum albumin (BSA), filter-sterilized and used for the next round of ion. The second round of selection was performed either on the same HA subtype or on HA of a different subtype.

Two utive rounds of selections were performed before isolation of individual single-chain phage antibodies. After the second round of selection, individual E.coli colonies were used to prepare monoclonal phage antibodies. Essentially, individual colonies were grown to log-phase in 96-well plate format and infected with VCS-M13 helper phages after which phage antibody production was allowed to proceed overnight.

The supernatants ning phage antibodies were used directly in ELISA for binding to HA antigens. Alternatively, phage dies were PEG/NaCl-precipitated and filtersterilized for both ELISA and flow cytometry analysis (usually done with clones which are positive in ELISA).

EXAMPLE 3 Validation of the HA specific single-chain phage antibodies Selected atants containing single-chain phage antibodies that were obtained in the screenings described above were validated in ELISA for icity, i.e. binding to different HA antigens. For this purpose, baculovirus-expressed recombinant influenza B HA (B/Ohio/01/2005, B/Malaysia/2506/2004, B/Jilin/20/2003, B/Brisbane/60/2008 and B/Florida/04/2006) (Protein es, CT, USA) was coated (0.5μg/ml) to MaxisorpTM ELISA plates. After coating, the plates were washed three times with PBS containing 0.1% v/v Tween-20 and d in PBS ning 2% ELK for 1 hr at room temperature. The selected single-chain phage antibodies were incubated for 1 hr in an equal volume of PBS containing 4% ELK to obtain blocked phage antibodies. The plates were emptied, washed three times with 1% Tween-20 and the blocked single-chain phage antibodies were added to the wells. Incubation was allowed to proceed for one hour; the plates were washed five times with PBS/0.1% Tween-20. Bound phage antibodies were detected (using OD 492nm measurement) using an anti-M13 antibody conjugated to peroxidase. As a control, the procedure was performed simultaneously without single-chain phage antibody and with an unrelated negative control single-chain phage antibody.

From the selections on the different HA antigens with the immune libraries, fourteen unique single-chain phage antibodies specific for both Yamagata-like and Victoria-like influenza B HA were obtained 031, sc08-032, sc08-033, sc08-034, sc08-035, sc08-059, sc10-023, sc10-032, 49, sc10-051, sc11-035, sc11-036, sc11- 038 and sc11-039). See Table 4.

These fourteen phage antibodies were used for construction of fully human immunoglobulins for further characterization (see Example 4).

EXAMPLE 4 Construction of fully human immunoglobulin molecules (human onal antibodies) from the selected single chain Fvs From the selected specific single-chain phage dies (scFv) clones, d DNA was obtained and nucleotide sequences were ined using standard sequencing techniques. The VH and VL gene identity of the scFvs was determined (see Table 5) using the IMGT/V-QUEST search page (Brochet, et al. (2008)).

The heavy chain variable region (VH) of the scFvs was cloned by restriction ion (SfiI/XhoI) for expression in the IgG expression vector pIg-C911-HCgamma1, which was digested with the same enzymes. The light le region (VL) was also cloned into its IgG designated expression vector pIG-C909-Ckappa , or pIg-C910- Clambda using SalI/NotI for the insert fragment and XhoI/NotI for the target vector, as described previously in To remove a potential de-amidation site in one of the antibodies (CR8059), a single amino acid mutant antibody (CR8071) was generated by assembly PCR. Two overlapping PCR fragments that each contained the desired mutation were ted.

These fragments were mixed in equimolar ratios and served as template in a second round PCR to obtain the full length LC sequence. Nucleotide sequences for all constructs were verified using standard sequencing techniques. The resulting expression ucts encoding the human IgG1 heavy and light chains were ently expressed together in HEK293T cells. After one week, the supernatants containing human IgG1 antibodies were ed and processed using standard purification procedures. The human IgG1 antibodies were titrated in a concentration range of between 10 to 0.003 μg/ml against influenza B HA antigen (data not shown). An unrelated antibody was included as a control antibody.

The amino acid sequence of the CDRs of both, heavy and light chain, of the selected immunoglobulin molecules is given in Table 5. The nucleotide sequence and amino acid ce of the heavy and light chain variable regions are given below.

EXAMPLE 5 Cross-binding reactivity of anti-influenza B IgGs The selected anti-influenza B antibodies were used to test h of binding by FACS analysis. For this purpose, full-length recombinant influenza B expression vectors coding for HA (B/Mississippi/04/2008, B/Houston/B60/1997, B/Nashville/45/1991, B/Florida/01/2009, B/Mississippi/07/2008 and B/Ohio/01/2005) were transfected into ® cells using lipofectamin (Invitrogen) in a 1 to 5 ratio. 48 hour after transfection, the PER.C6® cells expressing the nza B HA on the surface were analysed by FACS (CantoII, BD bioscience). Hereto the cells were incubated with IgG antibodies for 1 hour followed by three tial wash steps with PBS containing 0.1%BSA. Bound antibodies were detected using a PE-conjugated ary anti-human antibody which was also incubated for 1 hour. As a negative control, untransfected PER.C6® cells were used and incubated with the secondary antibody. The FACS results showed that the nza B binding antibodies CR8033, CR8059, CR8071, CR10032 and CR10051 showed binding to all six tested influenza B HAs (Table 6).

EXAMPLE 6 Competition for binding to HA of cross-reactive nfluenza B IgGs The anti-influenza B IgG antibodies described above were validated for ition for epitopes on influenza B HA. , B/Brisbane/60/2008, B/Florida/04/2006 and B/Jillin/20/2003 were labeled with biotin using the EZ-link Sulpho-NHS-LC-LC-biotin kit (Pierce). 1 µl of the 10 mM biotin solution was added to 110 µg of recombinant HA, which is a six-fold molar excess of biotin, and incubated for to 40 minutes at room temperature. The free unincorporated biotin was removed using an Amicon Ultra centrifugal filter (0.5 ml, 10K Ultracel-10K membrane; Millipore, cat#: UFC501096). Hereto the sample (300 µl) was loaded on the column and spun for 10 minutes at 14000 RPM in an Eppendorf tabletop centrifuge (20800 rcf). The flow trough was discarded and 0.4 ml DPBS buffer was loaded on the column and spun again. This step was repeated two times. The labeled sample was recovered by turning the column upside down into a new collector tube; then 200 µl DPBS was loaded and spun for 1 minute at 1000 rpm in a table top centrifuge. The HA concentration was measured using a Nanodrop ND-1000 apparatus (Thermo Scientific).

The actual competition experiment was done on an Octet-QK yer interferometry instrument Bio) according to the settings in Table 7 using streptavidin-coated biosensors (ForteBio, cat# 18-5019) that were pre-wetted for minutes in kinetic buffer at room temperature. When the second antibody was able to bind the Influenza B HA in the presence of the first, this was considered as noncompeting (see Table 8). As controls, stem-binding antibody CR9114 (as described in copending application EP11173953.8) and non-binding dy CR8057 (as described in WO2010/130636) were used.

Antibodies CR10023 and CR10049 compete for binding CR8033. Antibodies CR10032 and CR10051 compete for binding with CR8059. Antibody 9 competes for binding with CR10032. None of the tested dies compete with stem-binding antibody CR9114. These results indicate the ce of at least three to four different epitopes on the influenza B HA (Fig. 1).

EXAMPLE 7 Cross-neutralizing activity of IgGs In order to determine whether the selected IgGs were e of ng multiple influenza B strains, in vitro virus neutralization assays (VNAs) were performed. The VNAs were performed on MDCK cells (ATCC CCL-34) that were ed in MDCK cell culture medium (MEM medium supplemented with 20 mM Hepes and 0.15% (w/v) sodium bicarbonate (complete MEM medium), supplemented with 10% (v/v) fetal bovine serum). The influenza B Yamagata-like (B/Harbin/7/1994 and B/Florida/04/2006) and Victoria-like (B/Malaysia/2506/2004 and B/Brisbane/60/2008) strains used in the assay were all diluted to a titer of 5,7 x103 TCID50/ml (50% tissue culture infective dose per ml), with the titer calculated according to the method of Spearman and Karber. The IgG preparations (100 μg/ml) were serially 2-fold diluted (1:2 - 1:512) in te MEM medium in quadruplicate wells. 50μl of the respective IgG dilution was mixed with 50μl of virus suspension (100 TCID50/35μl) and incubated for one hr at 37°C. The suspension was then erred in quadruplicate into 96-well plates containing confluent MDCK cultures in 100μl complete MEM medium. Prior to use, MDCK cells were seeded at 2x104 cells per well in MDCK cell e , grown until cells had reached confluence, washed with 300-350 μl PBS, pH 7.4 and finally 100μl complete MEM medium was added to each well. The inoculated cells were cultured for 3 - 4 days at 37°C and observed daily for the development of cytopathogenic effect (CPE). CPE was compared to the positive control.

CR8032, CR8033, CR8034, CR8035, CR8059, CR8071, CR10023, CR10032, CR10049, CR10051, CR11035, CR11036, CR11038 and CR11039 all showed crossneutralizing activity to representative strains of both, ta and Victoria-like influenza B virus strains. See Table 9.

EXAMPLE 8 Receptor binding blocking activity of IgGs In order to determine whether the selected IgGs were capable of blocking the receptor mediated binding of nza B s to host cells, glutination inhibition (HI) assays were performed. The influenza B Yamagata-like (B/Harbin/7/1994 and B/Florida/04/2006) and Victoria-like (B/Malaysia/2506/2004 and B/Brisbane/60/2008) virus strains were diluted to 8 HA units, as determined in an HAU assay, and combined with an equal volume of serially diluted IgG and incubated for 1 hr at room ature. An equal volume of 0.5% Turkey red blood cells (TRBC) was added to the wells and incubation continued for 30 min. Button formation was scored as evidence of hemagglutination.

CR8059, CR8071, CR10032, CR10051 and CR11036 did not show HI ty to any of the tested influenza B virus strains (>10 µg/ml for CR11036, > 50 µg/ml for the other antibodies), indicating that they do not block the receptor binding. Antibodies CR8033 and CR10023 show HI activity to representative strains of only the Yamagata-, but not the Victoria-like influenza B virus strains. Antibody CR11035 shows HI activity to a representative strain of only the Victoria-, but not the Yamagata-like influenza B virus strains. Antibodies 9, CR11038 and CR11039 show HI activity to representative strains of both Yamagata and Victoria-like influenza B virus strains. See Table 10.

Alternatively, an immunofluorescence entry assay was designed to analyze the ability of a given antibody to block receptor binding and internalization of the virus.

Therefore, the virus was pre-incubated with the antibody in , ld dilution steps before being added to a confluent monolayer of MDCK cells plated in a l dish in infection medium (DMEM+200mM ine) for two to three hours. The inoculum was subsequently removed and replaced with antibody at indicated concentrations for 16 – 18 hrs at 37 °C, 5% CO2. After this time, the supernatants were d and the plates were fixed in 80% acetone for subsequent immunofluorescence ion by labeling infected cells using a mouse monoclonal anti-NP primary antibody (Santa Cruz, sc- 52027) and an Alexa488-coupled anti-mouse secondary antibody (Invitrogen A11017) followed by DAPI labeling of cellular nuclei (see Fig. 2a). As was seen with the HI assay, antibody CR8033 specifically d the viral entry of Yamagata-like virus B/Florida/04/2006 but not Victoria-like virus B/Malaysia/2506/2004. Antibody CR8059 did not block the entry of the tested nza B viruses. Some of the plates were uently analyzed using a BD Pathway 855 bioimager. To assess the level of entry inhibition, the fluorescence intensities per given well above a defined background and amount of infected cells (using DAPI stain to define a cell) was analyzed using BD Pathway imaging analysis tools. The percentage of infected cells treated with indicated dilutions of antibody compared to infected cells treated with a non-binding control antibody is displayed in Fig. 2b.

Egress inhibition of anti-HA IgGs To investigate the mechanism of action of the antibody, an egress assay was designed to analyze the amount of virus les released into the supernatant 18 hrs post infection under antibody treatment conditions. The detection (or absence) of an anti-HA signal after gel electrophoresis followed by Western blot of such supernatants is taken as indication for the presence (or absence) of released virus particles.

Four hours prior to the experiment, 40,000 MDCK cells per well were seeded in DMEM/glutamine into 96-well plates. The amount of virus needed to achieve 90-100% ion was titrated in a separate experiment. The required amount of virus was added to the cells and incubated at 37 °C, 5% CO2. After three hours, the supernatants were removed and cells were washed thrice with PBS to remove non-internalized virus particles. Cells were replenished with infection medium containing mAbs (serial dilution starting at l). After 16 – 18 hrs at 37 °C, 5% CO2, the supernatants were harvested and the remaining cells were lysed (Tris HCl pH 7.5, 150 mM NaCl, 5 mM EDTA, 1% (v/v) Triton-X). Samples were subjected to SDS-PAGE/Western blot to analyze the amount of virions released into the supernatant measured by developing the WB using a rabbit onal anti-HA staining (Protein es) followed by an HRP- coupled anti-rabbit 2-fragment (Jackson Immuno Research Laboratories, 111 047). As shown in Fig 3, both antibodies CR8033 and CR8059 inhibit the release of viral particles in a concentration ent manner. Further experiments have shown that at least CR8071 and CR10051 also inhibit the release of viral particles.

Proper infection of the cells was checked by fixing identically-treated wells with 80% acetone. The amount of infection was assessed using immunofluorescence labeling using a mouse monoclononal P primary antibody (Santa Cruz, sc-52027) and an Alexa488-coupled anti-mouse secondary antibody (Invitrogen A11017). The plates were subsequently analyzed using a BD Pathway 855 bioimager (results not .

EXAMPLE 10 Scanning electron microscopy of influenza B ed cells MDCK cells were seeded on glass coverslips one day prior to the experiment. The next day, cells were ed with different amounts of virus to determine the amount that yielded 90 – 100% infected cells after 18 hrs post infection. Three hours after the initial infection, the supernatants were removed; cells were washed thrice with PBS, before media containing the ted concentration of antibodies were added. After an additional 15 – 18 hrs, the cell e medium was removed and cells were fixed in 2.5% glutaraldehyde buffer and stored at 4 °C until further analysis. The samples were subjected to further chemical on using glutaraldehyde (GA) and/or osmium tetroxid (OsO4). Prior to SEM imaging, the specimens were subjected to acetone dehydration and critical-point-drying. Finally, the cells were be mounted on alumina stubs and coated with thin layer of carbon and examined in a Zeiss Ultra 55 SEM cope.

The e of influenza B infected MDCK cells is covered with electron dense spherical particles (Fig. 4b), in contrast to uninfected controls (Fig. 4a). Incubation with antibody CR8059 does not prevent the formation of these spherical particles (Fig. 4c) whereas incubation with antibody CR8033 greatly diminishes the formation of particles (Fig. 4d). In contrast to CR8059 incubated cells, budding virions can not readily be detected on CR8033 incubated cells (Fig. 4e and f).

EXAMPLE 11 Prophylactic activity of human IgG monoclonal antibodies against lethal influenza B challenge in vivo A study was performed to test the prophylactic effect of the monoclonal antibodies CR8033 and CR8071 against a lethal challenge with two influenza B s in vivo. MAbs CR8033 and CR8071 were tested for prophylactic cy in a mouse lethal challenge model with mouse adapted influenza B/Florida/04/2006 virus. The B/Florida/04/2006 virus was adapted to mice after 5 lung-to-lung es. The mouse adapted influenza B passage 5 virus was propagated in nated n eggs. All mice (Balb/c, female, age 6-8 weeks, n=8 per group) were acclimatized and maintained for a period of at least four days prior to the start of the experiment. MAbs CR8033 and CR8071 were dosed at 0.06, 0.2, 0.6, 1.7, and 5 mg/kg intravenously into the tail vein (vena coccygeus) at day -1 before challenge, assuming an average weight of 18 g per mouse and a fixed dose volume of 0.2 ml. A l group was taken along dosed with vehicle control. The mice were then nged at day 0 with 25 LD50 mouse adapted B/Florida/04/2006 influenza B virus by intranasal inoculation. Fig 5 shows the survival rates of the mice, following mAb administration. Mice dosed with dosages as low as 0.2 mg/kg for CR8033 and 0.6 mg/kg for CR8071 showed significantly higher survival rates than the vehicle treated control s.

Alternatively, mAbs CR8033 and CR8071 were tested for lactic efficacy in a mouse lethal challenge model with mouse adapted influenza B/Malaysia/2506/2004 virus. The B/Malaysia/2506/2004 virus was adapted to mice after 4 lung-to-lung passages. The mouse d influenza B passage 4 virus was propagated in embryonated chicken eggs. All mice (Balb/c, female, age 6-8 weeks, n=8 per group) were acclimatized and maintained for a period of at least four days prior to the start of the experiment.

MAbs CR8033 and CR8071 were dosed at 0.06, 0.2, 0.6, 1.7 and 5 mg/kg intravenously in the tail vein (vena coccygeus) at day -1 before nge, assuming an average weight of 18 g per mouse and a fixed dose volume of 0.2 ml. A control group was taken along dosed with vehicle control. The mice were then challenged at day 0 with 25 LD50 mouse adapted B/Malaysia/2506/2004 influenza B virus by intranasal inoculation. Fig. 5 shows the al rates of the mice, following mAb administration. Mice dosed with dosages as low as 0.2 mg/kg for CR8033 and 0.6 mg/kg for CR8071 showed significantly higher survival rates than the vehicle treated control animals.

These results show that human anti-influenza antibodies CR8033 and CR8071, identified and developed as disclosed , are able to provide in vivo tion against a lethal dose of influenza B viruses of both the B/Yamagata and the B/Victoria lineages when administered one day prior to infection at a dose equal to or higher than 0.2 or 0.6 mg/kg, respectively.

Table 1: Second round VL regions amplification overview Template 5’ primer 3’ primer t Share in Pool Share in PK/PL(%) VL (%) OK1S OJK1 K1J1 25 OK1S OJK2 K1J2 25 K1 OK1S OJK3 K1J3 10 PK1 30 OK1S OJK4 K1J4 25 OK1S OJK5 K1J5 15 OK2S OJK1 K2J1 25 OK2S OJK2 K2J2 25 K2 OK2S OJK3 K2J3 10 PK2 4 OK2S OJK4 K2J4 25 OK2S OJK5 K2J5 15 OK3S OJK1 K3J1 25 OK3S OJK2 K3J2 25 K3 OK3S OJK3 K3J3 10 PK3 1 OK3S OJK4 K3J4 25 OK3S OJK5 K3J5 15 OK4S OJK1 K4J1 25 OK4S OJK2 K4J2 25 K4 OK4S OJK3 K4J3 10 PK4 19 OK4S OJK4 K4J4 25 OK4S OJK5 K4J5 15 OK5S OJK1 K5J1 25 OK5S OJK2 K5J2 25 K5 OK5S OJK3 K5J3 10 PK5 1 OK5S OJK4 K5J4 25 OK5S OJK5 K5J5 15 OK6S OJK1 K6J1 25 OK6S OJK2 K6J2 25 K6 OK6S OJK3 K6J3 10 PK6 5 OK6S OJK4 K6J4 25 OK6S OJK5 K6J5 15 OL1S OJL1 L1J1 30 L1 OL1S OJL2 L1J2 60 PL1 14 OL1S OJL3 L1J3 10 OL2S OJL1 L2J1 30 L2 OL2S OJL2 L2J2 60 PL2 10 OL2S OJL3 L2J3 10 OL3S OJL1 L3J1 30 L3 OL3S OJL2 L3J2 60 PL3 10 OL3S OJL3 L3J3 10 OL4S OJL1 L4J1 30 L4 OL4S OJL2 L4J2 60 PL4 1 OL4S OJL3 L4J3 10 OL5S OJL1 L5J1 30 L5 OL5S OJL2 L5J2 60 PL5 1 OL5S OJL3 L5J3 10 OL6S OJL1 L6J1 30 L6 OL6S OJL2 L6J2 60 PL6 1 OL6S OJL3 L6J3 10 OL7S OJL1 L7J1 30 L7 OL7S OJL2 L7J2 60 PL7 1 OL7S OJL3 L7J3 10 OL8S OJL1 L8J1 30 L8 OL8S OJL2 L8J2 60 PL8 1 OL8S OJL3 L8J3 10 OL9S OJL1 L9J1 30 L9 OL9S OJL2 L9J2 60 PL9 1 OL9S OJL3 L9J3 10 VL 100% Table 2: Second round VH regions amplification ew Template 5’ primer 3’ primer Product Share in Pool Share in PK/PL VH (%) OH1S OJH1 H1J1 10 OH1S OJH2 H1J2 10 H1 OH1S OJH3 H1J3 60 PH1 25 OH1S OJH4 H1J4 20 OH2S OJH1 H2J1 10 OH2S OJH2 H2J2 10 H2 OH2S OJH3 H2J3 60 PH2 2 OH2S OJH4 H2J4 20 OH3S OJH1 H3J1 10 OH3S OJH2 H3J2 10 H3 OH3S OJH3 H3J3 60 PH3 25 OH3S OJH4 H3J4 20 OH4S OJH1 H4J1 10 OH4S OJH2 H4J2 10 H4 OH4S OJH3 H4J3 60 PH4 25 OH4S OJH4 H4J4 20 OH5S OJH1 H5J1 10 OH5S OJH2 H5J2 10 H5 OH5S OJH3 H5J3 60 PH5 2 OH5S OJH4 H5J4 20 OH6S OJH1 H6J1 10 OH6S OJH2 H6J2 10 H6 OH6S OJH3 H6J3 60 PH6 20 OH6S OJH4 H6J4 20 OH7S OJH1 H7J1 10 OH7S OJH2 H7J2 10 H7 OH7S OJH3 H7J3 60 PH7 1 OH7S OJH4 H7J4 20 VH 100% Table 3: Characteristics of the individual IgM memory B cell libraries.

Library Cells Used Library Intact size Orf MEMM08 540.000 IgM memory cells Facs sorted from 1 5.9E+07 donor MEMM09 775.000 IgM memory cells Facs sorted from 1 2.35E+07 donor MEMM10 700.000 IgM memory cells Facs sorted from 1 1.7E+07 donor Flu-PBMCM02 1E+07 total PBMC’s from 1 donor 1.0E+07 75% ellM03 280.000 Macs sorted B cells from 1 donor 2.0E+07 76% Flu-MEMM08 800.000 IgM memory cells Facs sorted from 1 2.4E+07 85% donor Flu-PBMCM03 3E+07 total PBMC’s from 3 donors (1E+07 2.8E+07 82% PBMC’s per donor) MCM04 3E+07 total PBMC’s from 3 donors (1E+07 3.1E+07 87% PBMC’s per donor) Flu-PBMCM05 3E+07 total PBMC’s from 3 donors (1E+07 3.3E+07 89% PBMC’s per donor) Flu-PBMCG01 4E+07 total PBMC’s from 4 donors (1E+07 >1E+07 82% PBMC’s per donor) Table 4: Binding of hages to recombinant Influenza B HA Yamagata Victoria B/Jilin/20/03 B/Florida/04/06 B/Malaysia/2506/04 B/ohio/01/05 B/Brisbane/60/08 sc08-031 ++ nt ++ ++ nt sc08-032 ++ nt ++ ++ nt sc08-033 ++ ++ ++ +++ ++ sc08-034 ++ nt ++ ++ nt sc08-035 ++ nt ++ ++ nt sc08-059 ++ ++ ++ ++ ++ sc10-023 ++ ++ + ++ + sc10-032 +++ +++ ++ +++ +++ sc10-049 +++ +++ +++ +++ +++ sc10-051 +++ +++ +++ +++ +++ sc11-035 nt +++ nt ++ ++ 36 nt +++ nt +++ +++ sc11-038 nt ++ nt ++ +++ sc11-039 nt +++ nt ++ +++ strong +++ binding ++ binding + weak binding - no binding nt not tested Table 5A: Amino acid sequences of HC CDRs of ed antibodies CR # VH locus CDR1-HC (SEQ ID NO) CDR2-HC(SEQ ID NO) CDR3-HC (SEQ ID NO) CR8033 9*01 YT (1) INWKGNFM (2) AKDRLESSAMDILEGGTFDI (3) CR8059 IGHV1-18*01 GYIFTESG (7) ISGYSGDT (8) ARDVQYSGSYLGAYYFDY (9) CR8071 IGHV1-18*01 GYIFTESG (7) ISGYSGDT (8) ARDVQYSGSYLGAYYFDY (9) CR10023 IGHV3-9*01 GFTFDDYA (14) INWVSTTM (15) AKDRLESAAIDILEGGTFDI (16) CR10032 IGHV4-39*02 GGSINSSPYK (20) FYYDGST (21) AAYCSSISCHAYYDYMNV (22) CR10049 IGHV3-23*04 GFTFSSYA (26) LSDESTT (27) AEDLGTVMDSYYYGMNV (28) CR10051 IGHV1-46*01 GDTFTNYH (31) INPSGGDT (32) ATDESPGLLTGLRDYWYYYGMDV CR11024 IGHV1-2*02 GYSFTGYY (35) INPISGDT (36) ARVAGEDWFGDLDY (37) CR11035 18*01 GYAFNGYG (40) INTYKVNT (41) ARDWGGPFGNAFDF (42) CR11036 IGHV1-46*01 GYAFTSYY (45) MNLHGGST (46) ARESPDSSGYPGYYGMDV (47) CR11038 IGHV1-46*01 GYAFTSYY (45) MNPHGGST (50) ARESPDSSGYPGYYGMDV (47) CR11039 GHV1-18*01 GYAFTGYG (54) INTYKFNT (55) ARDWAGPFGNAFDV (56) CR08031 IGHV3-9*01 YI (59) INWKGNFM (2) AKDRLESSAMDILEGGTFDI (3) CR08032 IGHV3-9*01 GFSFDEYI (61) INWKGNFM (2) AKDRLESSAMDILEGGTFDI (3) CR08034 IGHV3-9*01 GFTFDEYI (59) FM (2) AKDRLESSAMDILEGGTFDI (3) IGHV3-9*01 GFTFDEYI (59) INWKGNFM (2) AKDRLESSAMDILEGGTFDI (3) Table 5B Amino acid sequences of LC CDRs of ed antibodies CR # VL locus CDR1-LC (SEQ ID NO) C(SEQ ID NO) CDR3-LC (SEQ ID NO) CR8033 IGKV3-20*01 QSVSSSY (4) GAS (5) PWT (6) CR8059 IGLV1-47*01 SSNIGTNY (10) RSY (11) ATWDDSLNGWV (12) CR8071 47*01 SSNIGTNY (10) RSY (11) ATWDDSLDGWV (13) CR10023 8*01 SSDVGGYNY (17) DVS (18) SSYASGSTYV (19) CR10032 IGKV2-28*01 QSLRHENGYNY (23) LGS (24) MQALTQTLT (25) CR10049 IGKV2-28*01 QSLLHSNGLNY (29) LGS (24) MQALQTPFT (30) CR10051 IGKV3-20*01 QSVSSSY (4) GAS (5) QQYGSSPLCS (34) CR11024 IGKV3-20*01 QSVSSSY (4) GTS (38) QQYGSSPRT (39) CR11035 IGKV1-39*01 QSVGSY (43) GAS (5) QQSYSTPRT (44) CR11036 IGKV3-20*01 QSVSSDF (48) GTS (38) QQYGSSTWT (49) CR11038 IGLV1-44*01 RSNIGSNP (51) TND (52) AAWDDSLKGWV (53) CR11039 GHV1-18*01 QDISDY (57) GAS (5) QQYGNLPPT (58) CR08031 IGLV2-14*01 SSDVGGYNY (17) DVS (18) SSYTSSSTHV (60) CR08032 IGLV2-14*01 RRDVGDYKY (62) DVS (18) SSYTTSNTRV (63) 4 IGKV1-17*01 QGIRND (64) AAS (65) QQANTYPLT (66) CR08035 IGLV3-19*01 SLRSYY (67) GKN (68) DSRDSSGTHYV (69) Table 6: Binding of ed IgG to cell expressed Influenza B HA ta Victoria Nasvile/45/91 Mississippi/04/08 Houston/B0/97 Mississippi/07/08 Florida/01/09 Ohio/01/05 CR8031 ++ NT NT NT - NT CR8032 +++ + NT ++ - NT CR8033 ++ ++ ++ ++ ++ ++ CR8034 ++ NT NT NT - NT CR8035 +++ + +++ + - ++ CR8059 +++ +++ +++ +++ +++ +++ CR8071 +++ +++ +++ +++ +++ +++ CR10023 +++ - +++ - - - CR10032 +++ +++ +++ +++ +++ +++ CR10049 + - + - - + CR10051 ++ ++ ++ ++ ++ ++ +++ strong binding ++ binding + weak binding - no binding Table 7: Plate layout octet competition experiment Base line 1 Loading HA Baseline2 Association Association / 1st IgG (15 competition 2nd ug/ml) IgG (15 ug/ml) Duration 60 1200 60 700 700 (seconds) Row A Kinetic A Biotine Kinetic CR8033 CR8033 Row B buffer ed buffer CR8059 In 2nd Row C influenza B CR10023 measurement Row D HA CR10032 CR8059 etc Row E 10 ug/ml CR10049 Row F CR10051 Row G CR9114* Row I CR8057* *control antibodies 4: binding, CR8057 non-binding) Table 8: Competition experiment on influenza B HA CR8033 CR8059 CR10023 CR10032 9 CR10051 CR9114 CR8057 CR8033 X N Y N Y N N N CR8059 N X N Y N Y N N CR10023 Y N X Y Y N N N CR10032 N Y Y X Y Y N N CR10049 Y N Y N X N N N CR10051 N Y N Y N X N N CR9114 N N N N N N X N CR8057 - - - - - - - - Y: competition; N: no competition; X: self competition; -: No binding Table 9: Virus neutralization assays on influenza B virus strains VNA Yamagata Victoria titres in B/Harbin/7/199 B/Florida/04/200 ysia/2506/200 B/Brisbane/60/200 μg/ml 4 6 4 8 CR8031 1.24 0.88 >50* NT CR8032 0.69 0.69 3.88* NT CR8033 0.03 0.02 0.88* 5.95 CR8034 0.29 0.12 2.31* NT CR8035 0.66 0.66 4.46* NT CR8059 2.39 3.23 17.68* 4.55 CR8071 2.34 2.12 14.87* 3.72 CR10023 0.26 ≤0.55 12.5* 7.07 CR10032 12.5 21.02 53.03* 35.36 CR10049 4.42 1.3 25* 35.36 CR10051 0.28 0.63 1.77* 1.51 CR11035 0.16 ≤0.06 0.53* 0.93 CR11036 0.02 ≤0.06 0.22* ≤0.14 CR11038 0.05 ≤0.06 2.1* 0.55 9 0.02 ≤0.06 0.06* ≤0.14 NT: not tested * assay was done with 25TCIDs Table 10: Heamagglutination inhibition assay on influenza B virus strains HI Yamagata Victoria titres in B/Harbin/7/199 B/Florida/04/200 B/Malaysia/2506/200 B/Brisbane/60/200 μg/ml 4 6 4 8 CR8033 0.39 0.22 >50 >50 CR8059 >50 >50 >50 >50 CR8071 >50 >50 >50 >50 CR10023 1.1 1.56 >50 >50 CR10032 >50 >50 >50 >50 CR10049 >50 1.1 4.42 35.36 CR10051 >50 >50 >50 >50 CR11035 NT >10 NT 0.26 6 NT >10 NT >10 CR11038 NT 1.25 NT 0.31 CR11039 NT 0.63 NT 0.44 NT: not tested SEQUENCES >SC08-033 VH DNA (SEQ ID NO: 70) CAGCTGGTGGAGACTGGGGGAGGCCTGGTACAGCCTGGCAGGTCCCTGAGACTGTCCTGTGCAGCC TCTGGATTCAGCTTTGATGAGTACACCATGCATTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTC GCAGGTATTAATTGGAAAGGTAATTTCATGGGTTATGCGGACTCTGTCCAGGGCCGATTCACCATCTCCAGA GACAACGGCAAGAACTCCCTCTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCTTGTATTACTGT GCAAAAGACCGGCTGGAGAGTTCAGCTATGGACATTCTAGAAGGGGGTACTTTTGATATCTGGGGCCAAGGG ACAATGGTCACC >SC08-033 VH PROTEIN (SEQ ID NO: 71) EVQLVETGGGLVQPGRSLRLSCAASGFSFDEYTMHWVRQAPGKGLEWVAGINWKGNFMGYADSVQGRFTISR DNGKNSLYLQMNSLRAEDTALYYCAKDRLESSAMDILEGGTFDIWGQGTMVT >SC08-033 VL DNA (SEQ ID NO: 72) GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG GCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTC ATCTATGGTGCATCCACCAGGGCCACTGGTATCCCAGCCAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTC ACTCTCACCATCAGCAGACTGGAGCCTGAAGATCTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCG TGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAC >SC08-033 VL PROTEIN (SEQ ID NO: 73) SPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTDF TLTISRLEPEDLAVYYCQQYGSSPWTFGQGTKVEIK >SC08-059 VH DNA (SEQ ID NO: 74) GAGGTCCAGCTGGTACAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAGGGTCTCCTGCAGGGCC TCTGGTTACATCTTTACCGAATCTGGTATCACCTGGGTGCGCCAGGCCCCTGGACAAGGGCTTGAGTGGATG GGATGGATCAGCGGTTACAGTGGTGACACAAAATATGCACAGAAACTCCAGGGCAGAGTCACCATGACCAAA GACACATCCACGACCACAGCCTACATGGAATTGAGGAGCCTGAGATATGACGACACGGCCGTATATTACTGT GCGAGAGACGTCCAGTACAGTGGGAGTTATTTGGGCGCCTACTACTTTGACTATTGGAGCCCGGGAACCCTG GTCACCGTCTCGAGC >SC08-059 VH PROTEIN (SEQ ID NO: 75) EVQLVQSGAEVKKPGASVRVSCRASGYIFTESGITWVRQAPGQGLEWMGWISGYSGDTKYAQKLQGRVTMTK DTSTTTAYMELRSLRYDDTAVYYCARDVQYSGSYLGAYYFDYWSPGTLVTVSS >SC08-059 VL DNA (SEQ ID NO: 76) TCCTATGTGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATCTCTTGTTCTGGA AGCAGCTCCAACATCGGAACTAATTATGTATACTGGTACCAGCAGTTCCCAGGAACGGCCCCCAAACTCCTC ATCTATAGGAGTTATCAGCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCTCCTCAGCC TCCCTGGCCATCAGTGGGCTCCAGTCTGAGGATGAGGCTGATTATTACTGTGCAACATGGGATGACAGCCTG TGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAG >SC08-059 VL PROTEIN (SEQ ID NO: 77 SYVLTQPPSASGTPGQRVTISCSGSSSNIGTNYVYWYQQFPGTAPKLLIYRSYQRPSGVPDRFSGSKSGSSA SLAISGLQSEDEADYYCATWDDSLNGWVFGGGTKLTVL >CR08071 VH PROTEIN (SEQ ID NO: 78 SGAEVKKPGASVRVSCRASGYIFTESGITWVRQAPGQGLEWMGWISGYSGDTKYAQKLQGRVTMTK DTSTTTAYMELRSLRYDDTAVYYCARDVQYSGSYLGAYYFDYWSPGTLVTVSS >CR08071 VL PROTEIN (SEQ ID NO: 79) QSVLTQPPSASGTPGQRVTISCSGSSSNIGTNYVYWYQQFPGTAPKLLIYRSYQRPSGVPDRFSGSKSGSSA LQSEDEADYYCATWDDSLDGWVFGGGTKLTVLRK >SC10-051 VH DNA (SEQ ID NO: 80) GAGGTCCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCCTCAGTAGAACTTTCCTGCAAGGCA TCTGGAGACACCTTCACCAACTACCATATACACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATG GGAATAATCAATCCTAGTGGTGGTGACACAGACTACTCACAGAAGTTCCAGGGCAGAGTCACCCTGACCAGG GACAGGTCCACAAACACATTCTATATGAAGTTGGCCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGT GATGAGAGTCCCGGACTTTTGACTGGCCTTCGGGATTACTGGTACTACTACGGTATGGACGTCTGG GGCCAGGGGACCACGGTCACCGTCTCGAG >SC10-051 VH PROTEIN (SEQ ID NO: 81) EVQLVQSGAEVKKPGASVELSCKASGDTFTNYHIHWVRQAPGQGLEWMGIINPSGGDTDYSQKFQGRVTLTR DRSTNTFYMKLASLRSEDTAVYYCATDESPGLLTGLRDYWYYYGMDVWGQGTTVTVS >SC10-051 VL DNA (SEQ ID NO: 82) GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG GCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTC ATCTATGGTGCATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTC ACCATCAGCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCT AGTTTTGGCCAGGGGACCAAGCTGGAGATCAAAC >SC10-051 VL PROTEIN (SEQ ID NO: 83) EIVLTQSPGTLSLSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIYGASSRATGIPDRFSGSGSGTDF TLTISRLEPEDFAVYYCQQYGSSPLCSFGQGTKLEIK >SC10-049 VH DNA (SEQ ID NO: 84) GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGGTACAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGCCAGGCTCCAGGGAAGGGGCTGGAGTGGGTC TCACGTCTTAGTGATGAAAGTACCACATACTATGCAGACTCCGTGAAGGGCCGATTCACTATCTCCAGAGAC AATTCCAAGAACACACTGTATCTGCAGATGAACAGCCTGAAAGCCGACGACACGGCCATATATTACTGTGCG GAGGATCTGGGGACGGTGATGGACTCCTACTACTACGGTATGAACGTCTGGGGCCCAGGGACCACGGTCACC GTCTCGAG > SC10-049 VH PROTEIN (SEQ ID NO: 85) EVQLVESGGGLVQPGGSLRLSCAASGFTFSSYAMSWVRQAPGKGLEWVSRLSDESTTYYADSVKGRFTISRD NSKNTLYLQMNSLKADDTAIYYCAEDLGTVMDSYYYGMNVWGPGTTVTVS >SC10-049 VL DNA (SEQ ID NO: 86) GATGTTGTGATGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGG TCTAGTCAGAGCCTCCTGCATAGTAATGGACTCAATTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCT CCACAGCTCCTGATCTATTTGGGTTCTAATCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCA GGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCT CTACAAACTCCTTTCACTTTCGGCGGAGGGACCAAGGTGGAGATCAAAC >SC10-049 VH N (SEQ ID NO: 87) DVVMTQSPLSLPVTPGEPASISCRSSQSLLHSNGLNYLDWYLQKPGQSPQLLIYLGSNRASGVPDRFSGSGS GTDFTLKISRVEAEDVGVYYCMQALQTPFTFGGGTKVEIK >SC10-023 VH DNA (SEQ ID NO: 88) GAGGTGCAGCTGGTGGAGACTGGGGGAGGCTTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCACCTTTGATGATTATGCCATGCATTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTC TCAGGTATTAATTGGGTTAGTACTACCATGGGCTATGCGGACTCTGTGAAGGGCCGATTCACCATCTCCAGA GACAACGCCAAGAACTCCCTGTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCTTGTATTACTGT GCAAAAGATAGGCTGGAGAGTGCAGCTATAGACATTCTAGAAGGGGGTACTTTTGATATCAGGGGCCAAGGG ACAATGGTCACCGTCTCGAGCG >SC10-023 VH PROTEIN (SEQ ID NO: 89) EVQLVETGGGLVQPGRSLRLSCAASGFTFDDYAMHWVRQAPGKGLEWVSGINWVSTTMGYADSVKGRFTISR DNAKNSLYLQMNSLRAEDTALYYCAKDRLESAAIDILEGGTFDIRGQGTMVTVSS >SC10-023 VL DNA (SEQ ID NO: 90) CAGTCTGCCCTGACTCAGCCTCCCTCCGCGTCCGGCTCTCCTGGACAGTCAGTCACCATCTCCTGCACTGGA ACCAGCAGTGATGTTGGTGGTTATAACTATGTCTCCTGGTACCAACAGCACCCAGGCAAAGCCCCCAAACTC ATGATTTATGATGTCAGTAAGCGGCCCTCAGGGGTCCCTGATCGCTTCTCTGGGTCCAAGTCTGGCAACACG GCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGCTGAATATTACTGCAGCTCATATGCAAGCGGC AGCACTTATGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAG >SC10-023 VL PROTEIN (SEQ ID NO: 91) QSALTQPPSASGSPGQSVTISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSKRPSGVPDRFSGSKSGNT ASLTISGLQAEDEAEYYCSSYASGSTYVFGTGTKVTVL >SC10-032 VH DNA (SEQ ID NO: 92) CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGAAGCCTTCGGGCACCCTGTCCCTCACCTGCAATGTC TCTGGTGGCTCCATCAACAGTAGTCCCTATAAGTGGGCCTGGATCCGCCAGTCCCCAGGGAAGGGGCTGGAG TGGATTGGGACTTTCTATTATGATGGGAGCACCGACTACAACCCGTCCCTCCAGAGTCGACTCACCATTTCC GGAGACATGTCCAGTAACCACTTCTCCTTGAGGCTGAGGTCTGTGACCGCCGCAGACACGGCTGTGTATTAC TGTGCGGCCTATTGTAGTAGTATAAGCTGCCATGCCTATTACGACTACATGAACGTCTGGGGCAAAGGGACC ACCGTCTCGAGC >SC10-032 VH PROTEIN (SEQ ID NO: 93) QVQLQESGPGLVKPSGTLSLTCNVSGGSINSSPYKWAWIRQSPGKGLEWIGTFYYDGSTDYNPSLQSRLTIS HFSLRLRSVTAADTAVYYCAAYCSSISCHAYYDYMNVWGKGTTVTVSS >SC10-032 VL DNA (SEQ ID NO: 94) GAAATTGTGCTGACTCAGTCTCCACTCTCCCTGCCCGTCACCCCTGGAGAGCCGGCCTCCATCTCCTGCAGG TCTAGTCAGAGCCTCCGACATGAGAATGGATACAACTATTTGGATTGGTACCTGCAGAAGCCAGGGCAGTCT CCACAGCTCCTGATGTATTTGGGTTCTGTTCGGGCCTCCGGGGTCCCTGACAGGTTCAGTGGCAGTGGATCA GGCACAGATTTTACACTGAAAATCAGCAGAGTGGAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAGCT CTACAAACGCTCACTTTCGGCGGAGGGACCAAGCTGGAGATCAAAC 032 VL PROTEIN (SEQ ID NO: 95) EIVLTQSPLSLPVTPGEPASISCRSSQSLRHENGYNYLDWYLQKPGQSPQLLMYLGSVRASGVPDRFSGSGS GTDFTLKISRVEAEDVGVYYCMQALQTLTFGGGTKLEIK >SC11-024 VH DNA (SEQ ID NO: 96) CAGCTGGTGCAGTCTGGGGCTGAAATTAAGAAGCCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCT TCTGGATACAGCTTCACCGGCTACTATATGCACTGGGTGCGACAGGCCCCTGGACAAGGACCTGAGTGGATG GGGCGGATCAACCCTATCAGTGGTGACACAAACTATGCACAGAGGTTTCAGGGCAGGGTCACCTTGACCAGG GACAGGTCCACCAGCACAGCCTACATGGAGCTGAGCGGGCTGAAATCTGACGACACGGCCGTATATTTCTGT GCGAGAGTCGCGGGTGAAGATTGGTTCGGGGATCTTGACTATTGGGGCCAGGGAACCCTGGTCACCGTCTCG >SC11-24 VH PROTEIN (SEQ ID NO: 97) EVQLVQSGAEIKKPGASVKVSCKASGYSFTGYYMHWVRQAPGQGPEWMGRINPISGDTNYAQRFQGRVTLTR DRSTSTAYMELSGLKSDDTAVYFCARVAGEDWFGDLDYWGQGTLVTVSS >SC11-024 VL DNA (SEQ ID NO: 98) GAAATTGTGTTGACGCAGTCTCCAGCCACCCTGTCTGTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG GCCAGTCAGAGTGTTAGCAGCAGCTACTTAGCCTGGTACCAGCAGAAACCTGGCCAGGCTCCCAGGCTCCTC ATCTTTGGAACATCCAGCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTC ACTCTCACCATCAGCAGGCTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCACCT TTCGGCCAAGGGACCAAGGTGGAGATCAAAC >SC11-024 VL PROTEIN (SEQ ID NO: 99) EIVLTQSPATLSVSPGERATLSCRASQSVSSSYLAWYQQKPGQAPRLLIFGTSSRATGIPDRFSGSGSGTDF TLTISRLEPEDFAVYYCQQYGSSPRTFGQGTKVEIK >SC11-035 VH DNA (SEQ ID NO: 100) CAGGTGCAGCTGGTACAGTCTGGAGCTGAGGTGAAGAAGCCTGGGTCCTCGGTGAAGGTCTCCTGCAAGACC TCTGGTTACGCCTTTAACGGCTACGGTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGGTG GCATGGATCAACACTTACAAAGTTAACACACATTATGCACAGAATCTCCGGGGCAGGGTCACCGTGAGCATA GACACATCCACGACCACAGCCTATATGGAACTGAGGAGCCTGAGATCTGACGACACGGCCGTCTATTACTGT GCGAGAGACTGGGGTGGGCCGTTTGGGAACGCTTTTGATTTCTGGGGCCAAGGGACAATGGTCACCGTCTCG >SC11-035 VH PROTEIN (SEQ ID NO: 101) SGAEVKKPGSSVKVSCKTSGYAFNGYGISWVRQAPGQGLEWVAWINTYKVNTHYAQNLRGRVTVSI AYMELRSLRSDDTAVYYCARDWGGPFGNAFDFWGQGTMVTVSS >SC11-035 VL DNA (SEQ ID NO: 102) GACATCCAGATGACCCAGTCTCCATCCTCCCTGGCTGCATCTATAGGAGACAGTGTCACCATCACTTGCCGG GCAAGTCAGAGCGTTGGCTCTTACTTAAATTGGTATCAGCAAAAACCAGGGAAAGCCCCTAAGTTGTTGATC TATGGTGCATCCAATGTGCAAAGTGGGGTCCCATCAAGGTTTAGTGGCAGTGAGTCTGGGACAGAGTCCACA CTCACCATCAACAATCTGCAGCCTGAAGATTCTGCAACTTACTACTGTCAACAGAGTTACAGTACCCCTAGA ACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAC 035 VL PROTEIN (SEQ ID NO: 103) DIQMTQSPSSLAASIGDSVTITCRASQSVGSYLNWYQQKPGKAPKLLIYGASNVQSGVPSRFSGSESGTEST LTINNLQPEDSATYYCQQSYSTPRTFGQGTKVEIK >SC11-036 VH DNA (SEQ ID NO: 104) CAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGACGGTTTCCTGCAAGGCA TCTGGATACGCCTTCACCAGCTACTATTTACACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATG GGGATAATGAATCTTCATGGTGGTAGCACAACCTACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGG GACACGTCCACGAGGACAGTTTACATGGAGCTGAGCGGCCTGAGATCTGAGGACTCGGCCGTATATTACTGT GCCCGAGAGAGTCCCGATAGCAGTGGTTATCCTGGCTACTACGGTATGGACGTCTGGGGCCAGGGGACCACG GTCACCGTCTCGAGC >SC11-036 VH PROTEIN (SEQ ID NO: 105) EVQLVQSGAEVKKPGASVTVSCKASGYAFTSYYLHWVRQAPGQGLEWMGIMNLHGGSTTYAQKFQGRVTMTR DTSTRTVYMELSGLRSEDSAVYYCARESPDSSGYPGYYGMDVWGQGTTVTVSS >SC11-036 VL DNA (SEQ ID NO: 106) GAAATTGTGTTGACGCAGTCTCCAGGCACCCTGTCTTTGTCTCCAGGGGAAAGAGCCACCCTCTCCTGCAGG GCCAGTCAGAGTGTTAGCAGCGACTTCTTCGCCTGGTACCAGCAGAAACGTGGCCAGACTCCCACCCTCCTC ATCTATGGTACATCCACCAGGGCCACTGGCATCCCAGACAGGTTCAGTGGCAGTGGGTCTGGGACAGACTTC ACACTCAGCGTCGCCAGACTGGAGCCTGAAGATTTTGCAGTGTATTACTGTCAGCAGTATGGTAGCTCGACG TGGACGTTCGGCCAAGGGACCAAGGTGGAAATCAAAC >SC11-036 VL PROTEIN (SEQ ID NO: 107) EIVLTQSPGTLSLSPGERATLSCRASQSVSSDFFAWYQQKRGQTPTLLIYGTSTRATGIPDRFSGSGSGTDF TLSVARLEPEDFAVYYCQQYGSSTWTFGQGTKVEIK >SC11-038 VH DNA (SEQ ID NO: 108) GAGGTGCAGCTGGTGGAGTCTGGGGCTGAGGTGAAGAAGCCTGGGGCCTCAGTGAAGGTTTCCTGCAAGGCA TCTGGATACGCCTTCACCAGCTACTATTTGCACTGGGTGCGACAGGCCCCTGGACAAGGGCTTGAGTGGATG GGGATAATGAACCCTCATGGTGGTAGCACAACCTACGCACAGAAGTTCCAGGGCAGAGTCACCATGACCAGG GACACGTCCACGAGCACAGTCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACGGCCGTGTATTACTGT GCCCGAGAGAGTCCCGATAGTAGTGGTTATCCTGGCTACTACGGTATGGACGTCTGGGGCCAAGGGACCACG GTCTCGAGC >SC11-038 VH PROTEIN (SEQ ID NO: 109) EVQLVESGAEVKKPGASVKVSCKASGYAFTSYYLHWVRQAPGQGLEWMGIMNPHGGSTTYAQKFQGRVTMTR DTSTSTVYMELSSLRSEDTAVYYCARESPDSSGYPGYYGMDVWGQGTTVTVSS >SC11-038 VL DNA (SEQ ID NO: 110) GAGCTGACTCAGCCACCCTCAGCGTCTGGGACCCCCGGGCAGAGGGTCACCATGTCTTGTTCTGGA AGCAGATCCAACATCGGATCTAATCCTGTAAGCTGGTTCCAGCAACTCCCGGGAATGGTCCCCAAACTCCTC ATCTATACTAATGATCAGCGGCCCTCAGGGGTCCCTGACCGATTCTCTGGCTCCAAGTCTGGCCCCTCAGCC TCCCTGGCCATCAGTGGGCTCCAGTCTGAGGATGAGGCTGATTATTACTGTGCAGCATGGGATGACAGCCTG AAAGGTTGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAG >SC11-038 VL N (SEQ ID NO: 111) SYELTQPPSASGTPGQRVTMSCSGSRSNIGSNPVSWFQQLPGMVPKLLIYTNDQRPSGVPDRFSGSKSGPSA SLAISGLQSEDEADYYCAAWDDSLKGWVFGGGTKLTVL >SC11-039 VH DNA (SEQ ID NO: 112) GAGGTCCAGCTGGTACAGTCTGGAGCAGAGGTGAAAAAGCCCGGGGAGTCTGTGAAGATCTCCTGTAAGACT TCTGGTTACGCCTTTACCGGCTACGGTATCAGCTGGGTGCGACAGGCCCCTGGACAAGGCCTTGAGTGGATG GGATGGATCAACACTTACAAATTTAACACAAATTATGCACAGAACCTGCAGGGCAGAGTCACCATGACCATA GACACATCCACGAGCGCAGCCTACATGGAGCTGAGGAGCCTGAGATATGAGGACACGGCCGTATATTTCTGT GCGAGAGACTGGGCTGGGCCGTTTGGGAATGCTTTTGATGTCTGGGGCCAGGGGACAATGGTCACCGTCTCG >SC11-039 VH PROTEIN (SEQ ID NO: 113) EVQLVQSGAEVKKPGESVKISCKTSGYAFTGYGISWVRQAPGQGLEWMGWINTYKFNTNYAQNLQGRVTMTI DTSTSAAYMELRSLRYEDTAVYFCARDWAGPFGNAFDVWGQGTMVTVSS >SC11-039 VL DNA (SEQ ID NO: 114) ACATCCAGATGACCCAGTCTCCATCTTCCCTGTCTGCATCTATAGGAGACAGAGTCGCCATCACTTGCCAGG CGAGTCAGGACATTAGCGACTATTTAAATTGGTATCAGCAACAACCAGGGAAAGCCCCTAAGCTCCTGCTCT ACGGTGCATCCAATTTGGAAACAGGGGTCCCATCAAGGTTCAGTGGAAGTGGATCTGGGACAGATTTTACTT TCACCATCAGCAGCCTGCAGCCTGAAGACATTGCAACATATTATTGTCAACAGTATGGTAATCTCCCTCCGA CTTTCGGCGGGGGGACCAAGCTGGAGATCAAAC >SC11-039 VL PROTEIN (SEQ ID NO: 115) PSSLSASIGDRVAITCQASQDISDYLNWYQQQPGKAPKLLLYGASNLETGVPSRFSGSGSGTDFTF TISSLQPEDIATYYCQQYGNLPPTFGGGTKLEIK >SC09-114 VH PROTEIN (SEQ ID NO: 116) QVQLVQSGAEVKKPGSSVKVSCKSSGGTSNNYAISWVRQAPGQGLDWMGGISPIFGSTAYAQKFQGRVTISA DIFSNTAYMELNSLTSEDTAVYFCARHGNYYYYSGMDVWGQGTTVTVSS >SC09-114 VL PROTEIN (SEQ ID NO: 117) SYVLTQPPAVSGTPGQRVTISCSGSDSNIGRRSVNWYQQFPGTAPKLLIYSNDQRPSVVPDRFSGSKSGTSA SLAISGLQSEDEAEYYCAAWDDSLKGAVFGGGTQLTVL >SC08-031 VH DNA (SEQ ID NO: 118) GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCACCTTTGATGAGTATATCATGCATTGGGTCCGGCAAGCTCCCGGGAAGGGCCCGGAATGGGTC GCAGGTATTAATTGGAAAGGTAATTTCATGGGTTATGCGGACTCTGTCCAGGGCCGATTCACCATCTCCAGA GACAACGCCAAGAACTCCCTCTATCTGCAAATGAACAGTCTGAGAGCTGACGACACGGCCTTATATTACTGT GCAAAAGACCGGCTGGAGAGTTCAGCTATGGACATTCTAGAAGGGGGTACTTTTGATATCTGGGGCCAAGGG GTCACC >SC08-031 VH PROTEIN (SEQ ID NO:119) EVQLVESGGGLVQPGRSLRLSCAASGFTFDEYIMHWVRQAPGKGPEWVAGINWKGNFMGYADSVQGRFTISR LYLQMNSLRADDTALYYCAKDRLESSAMDILEGGTFDIWGQGTMVT >SC08-031 VL DNA (SEQ ID NO: 120) CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGA ACCAGCAGTGACGTTGGTGGTTATAACTATGTCTCCTGGTACCAACAGCACCCAGGCAAAGCCCCCAAACTC ATGATTTATGATGTCAGTAGTCGGCCCTCAGGGGTTTCTAATCGCTTCTCTGGCTCCAAGTCTGGCGACACG GCCTCCCTGAGCATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCAGCTCATATACAAGCAGC AGCACTCATGTCTTCGGAACTGGGACCAAGGTCACCGTCCTAG >SC08-031 VL PROTEIN (SEQ ID NO:121) QSALTQPASVSGSPGQSITISCTGTSSDVGGYNYVSWYQQHPGKAPKLMIYDVSSRPSGVSNRFSGSKSGDT ASLSISGLQAEDEADYYCSSYTSSSTHVFGTGTKVTVL >SC08-032 VH DNA (SEQ ID NO: 122) CAGCTGGTGGAGTCTGGGGGAGGCCTGGTACAGCCTGGCAGGTCCCTGAGACTGTCCTGTGCAGCC TCTGGATTCAGCTTTGATGAGTACATCATGCATTGGGTCCGGCAAGCTCCAGGGAAGGGCCTGGAGTGGGTC GCAGGTATTAATTGGAAAGGTAATTTCATGGGTTATGCGGACTCTGTCCAGGGCCGATTCACCATCTCCAGA GACAACGGCAAGAACTCCCTCTATCTGCAAATGAACAGTCTGAGAGCTGAGGACACGGCCTTGTATTACTGT GCAAAAGACCGGCTGGAGAGTTCAGCTATGGACATTCTAGAAGGGGGTACTTTTGATATCTGGGGCCAAGGG ACAATGGTCACCGTCTCGAGC >SC08-032 VH N (SEQ ID NO:123) EVQLVESGGGLVQPGRSLRLSCAASGFSFDEYIMHWVRQAPGKGLEWVAGINWKGNFMGYADSVQGRFTISR LYLQMNSLRAEDTALYYCAKDRLESSAMDILEGGTFDIWGQGTMVTVSS >SC08-032 VL DNA (SEQ ID NO: 124) CAGTCTGCCCTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCCTGCACTGGA ACCCGCAGGGACGTTGGTGATTATAAGTATGTCTCCTGGTACCAACAACACCCAGGCAAAGCCCCCAAACTC ATGATTTATGATGTCAGTAATCGGCCCTCAGGGGTCTCTAATCGCTTCTCTGGCTCCAAGTCTGGCACCACG GCCTCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGCTGATTATTATTGCAGTTCATACACAACCAGC AACACTCGGGTGTTCGGCGGAGGGACCAAGCTGACCGTCCTAG >SC08-032 VL PROTEIN (SEQ ID NO:125) QSALTQPASVSGSPGQSITISCTGTRRDVGDYKYVSWYQQ ASLTISGLQAEDEADYYCSSYTTSNTRVFGGGTKLTVL >SC08-034 VH DNA (SEQ ID NO: 126) GAGGTGCAGCTGGTGGAGACTGGGGGAGGCCTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCACCTTTGATGAGTATATCATGCATTGGGTCCGGCAAGCTCCCGGGAAGGGCCCGGAATGGGTC GCAGGTATTAATTGGAAAGGTAATTTCATGGGTTATGCGGACTCTGTCCAGGGCCGATTCACCATCTCCAGA GACAACGCCAAGAACTCCCTCTATCTGCAAATGAACAGTCTGAGAGCTGACGACACGGCCTTATATTACTGT GCAAAAGACCGGCTGGAGAGTTCAGCTATGGACATTCTAGAAGGGGGTACTTTTGATATCTGGGGCCAAGGG ACAATGGTCACCGTCTCGAGC >SC08-034 VH PROTEIN (SEQ ID NO: 127) EVQLVETGGGLVQPGRSLRLSCAASGFTFDEYIMHWVRQAPGKGPEWVAGINWKGNFMGYADSVQGRFTISR DNAKNSLYLQMNSLRADDTALYYCAKDRLESSAMDILEGGTFDIWGQGTMVTVSS >SC08-034 VL DNA (SEQ ID NO: 128) GACATCCAGATGACCCAGTCTCCATCCTCCCTGTCTGCATCTGTGGGAGACAGAGTCACCATCACTTGCCGG GCAAGTCAGGGCATTAGAAATGATTTAGGCTGGTATCAGCAGAAACCAGGGAAAGCCCCTAAGCGCCTGATC TATGCTGCATCCAGTTTGCAAAGTGGGGTCCCATCAAGGTTCAGTGGCAGTGGATCTGGGACAGATTTCACT CTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACTTACTATTGTCAACAGGCTAACACTTATCCACTC ACTTTCGGCGGAGGGACCAAGCTGGAGATCAAAC >SC08-034 VL PROTEIN (SEQ ID NO:129) DIQMTQSPSSLSASVGDRVTITCRASQGIRNDLGWYQQKPGKAPKRLIYAASSLQSGVPSRFSGSGSGTDFT LTISSLQPEDFATYYCQQANTYPLTFGGGTKLEIK >SC08-035 VH DNA (SEQ ID NO: 130) GAGGTGCAGCTGGTGGAGTCTGGGGGAGGCCTGGTACAGCCTGGCAGGTCCCTGAGACTCTCCTGTGCAGCC TCTGGATTCACCTTTGATGAGTATATCATGCATTGGGTCCGGCAAGCTCCCGGGAAGGGCCCGGAATGGGTC GCAGGTATTAATTGGAAAGGTAATTTCATGGGTTATGCGGACTCTGTCCAGGGCCGATTCACCATCTCCAGA GACAACGCCAAGAACTCCCTCTATCTGCAAATGAACAGTCTGAGAGCTGACGACACGGCCTTATATTACTGT GCAAAAGACCGGCTGGAGAGTTCAGCTATGGACATTCTAGAAGGGGGTACTTTTGATATCTGGGGCCAAGGG GTCACCGTCTCGAGC 035 VH PROTEIN (SEQ ID NO: 131) EVQLVESGGGLVQPGRSLRLSCAASGFTFDEYIMHWVRQAPGKGPEWVAGINWKGNFMGYADSVQGRFTISR DNAKNSLYLQMNSLRADDTALYYCAKDRLESSAMDILEGGTFDIWGQGTMVTVSS >SC08-035 VL DNA (SEQ ID NO: 132) TCTTCTGAGCTGACTCAGGACCCTGCTGTGTCTGTGGCCTTGGGACAGACAGTCAGGATCACATGCCAAGGA CTCAGAAGCTATTATGCAAGCTGGTACCAGCAGAAGCCAGGACAGGCCCCTGTACTTGTCATCTAT GGTAAAAACAACCGGCCCTCAGGGATCCCAGACCGATTCTCTGGCTCCAGCTCAAGAAACACAGCTTCCTTG ACCATCACTGGGGCTCAGGCGGAAGATGAGGCTGACTATTATTGTGACTCCCGGGACAGCAGTGGAACCCAT TATGTCTTCGGAGGTGGGACCAAGGTCACCGTCCTAG >SC08-035 VL PROTEIN (SEQ ID NO: 133) SSELTQDPAVSVALGQTVRITCQGDSLRSYYASWYQQKPGQAPVLVIYGKNNRPSGIPDRFSGSSSRNTASL TITGAQAEDEADYYCDSRDSSGTHYVFGGGTKVTVL REFERENCES Brochet et al., Nucl. Acids Res. 36, W503-508 (2008).

De Kruif J et al., Proc. Natl. Acad. Sci. USA 92:3938 (1995).

Kanegae et al., J. Virol. 64: 2860-2865 .

Kubota-Koketsu et al., Biochem. Biophys. Res. Comm. 387: 180-185 (2009).

Rota et al., J. Gen. Virol. 73: 2737-2742 (1992).

Thompson et al. JAMA 289(2): 179-186 (2003).

Thompson et al., JAMA 292(11): 1333-1340 (2004).

Wrammert et al., Nature 453: 667-672 (2008).

The term "comprising" as used in this specification and claims means "consisting at least in part of". When interpreting statements in this specification, and claims which include the term "comprising", it is to be understood that other es that are additional to the features ed by this term in each statement or claim may also be t. Related terms such as "comprise" and "comprised" are to be interpreted in similar manner.

In this specification where reference has been made to patent ications, other external documents, or other s of information, this is generally for the purpose of providing a context for discussing the features of the invention. Unless ically stated otherwise, reference to such external documents is not to be construed as an admission that such documents, or such sources of information, in any jurisdiction, are prior art, or form part of the common general knowledge in the art.

In the description in this ication reference may be made to subject matter that is not within the scope of the claims of the current application. That subject matter should be readily identifiable by a person skilled in the art and may assist in putting into practice the invention as defined in the claims of this application.

Claims (21)

WHAT WE CLAIM IS:

1. A binding molecule capable of specifically binding to hemagglutinin (HA) of nza B virus strains of the B/Yamagata and B/Victoria lineage, and e of neutralizing said influenza B virus strains of the B/Yamagata and/or B/Victoria lineage, wherein the binding molecule does not bind to HA of influenza A viruses, wherein the binding molecule comprises a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 1, a heavy chain CDR2 comprising the amino acid sequence of SEQ ID NO: 2, and a heavy chain CDR3 comprising the amino acid sequence of SEQ ID NO: 3, and a light chain CDR1 comprising the amino acid sequence of SEQ ID NO: 4, a light chain CDR2 comprising the amino acid sequence of SEQ ID NO: 5, and a light chain CDR3 comprising the amino acid sequence of SEQ ID NO:6.

2. A binding molecule according to claim 1, wherein the binding molecule binds to the head region of the HA protein of influenza B s, in particular to the head region of HA1of influenza B s.

3. A binding molecule according to claim 1 or 2, wherein the binding molecule comprises a heavy chain variable region comprising the amino acid ce set forth in SEQ ID NO: 71 or a sequence of amino acids having 80 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more ce ty thereto.

4. A binding molecule according to claim 3, wherein the binding molecule comprises a light chain variable region comprising the amino acid sequence set forth in SEQ ID NO: 73, or a sequence of amino acids having 80 %, 90 %, 91 %, 92 %, 93 %, 94 %, 95 %, 96 %, 97 %, 98 %, 99 % or more ce identity thereto.

5. A binding molecule according to claim 3 or 4, wherein the binding molecule comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 71 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 73.

6. A binding molecule according to any one of the claims 1-5, wherein the binding molecule inhibits egress of influenza B virus from infected cells.

7. A binding molecule according to any one of the preceding claims, n the binding molecule is a human monoclonal antibody, or an antigen-binding fragment thereof.

8. An conjugate, comprising at least one binding molecule ing to any one of the preceding claims and further comprising at least one tag.

9. A nucleic acid le encoding a binding molecule according to any one of claims 1-7.

10. A binding molecule ing to any one of claims 1-7, an immunoconjugate according to claim 8, or a nucleic acid molecule according to claim 9, for use as a medicament.

11. A binding molecule, an immunoconjugate or a nucleic acid le according to claim 10 for use in the diagnosis, prophylaxis and/or treatment of an influenza infection caused by an influenza B virus.

12. A use of a binding molecule according to any one of claims 1-7, an immunoconjugate according to claim 8, or a nucleic acid molecule according to claim 9, in the manufacture of a medicament.

13. A use of a binding molecule according to any one of claims 1-7, an immunoconjugate according to claim 8, or a nucleic acid molecule according to claim 9, in the manufacture of a medicament for use in the diagnosis, prophylaxis and/or treatment of an influenza infection caused by an influenza B virus.

14. A pharmaceutical composition comprising a binding molecule according to any of the claims 1-7, or an immunoconjugate according to claim 8, and a pharmaceutically acceptable carrier or excipient.

15. A method of detecting an nza B virus infection comprising: (a) assaying the level of influenza B virus antigen in a biological sample using a binding molecule according to claim 1-7, or an immunoconjugate according to claim 8; (b) comparing the assayed level of influenza B virus antigen with a control level whereby an increase in the assayed level of influenza B virus antigen compared to the control level of the nza B virus antigen is indicative of an influenza B virus infection.

16. A binding le as d in claim 1 substantially as herein described or exemplified and with or without nce to the anying drawings.

17. An immunoconjugate as claimed in claim 8 substantially as herein described or ified and with or without reference to the accompanying drawings.

18. A nucleic acid as claimed in claim 9 substantially as herein described or exemplified and with or t reference to the accompanying drawings.

19. A use as claimed in claim 12 or 13 substantially as herein described or exemplified and with or without reference to the anying drawings.

20. A pharmaceutical composition as claimed in claim 14 substantially as herein described or ified and with or without reference to the accompanying drawings.

21. A method as claimed in claim 15 substantially as herein described or exemplified and with or without reference to the accompanying drawings. CR8033 CR10049 CR10032 CR8059 III CR10051 CR9114 IV SUBSTITUTE SHEET (RULE 26) o o U) o o -4 hS n H W hS o u< o o> o a\ KJ 0\ > ^ O Yamagata-like (B/Florida/04/2006) Victoria-like -' (B/Malaysia/2506/2004) »*?• ,r ! H : - Mg/ml) ; •-•;> CR8033 (5 ' "I v.--: & x -'• '• Mg/ml) .«• : . . '•< '' *- 0 . • %>•••£*' o />-"•. 1 E^ts^ • • - ^ 'V . ! • cy-. • - -' ' .'• • .'^If - - - f. • ». «r... L ^4^ rl CR8059 (50 'W'j ^ 'V/. ^ c fc " nC>_ ^ * A, v * f " v './•> \y No ^ij m LTi m m H 73 c= Ln CI UD LTi H H a H m NJ oi $ 60 S? • CR8033 •CR8059 1:1 1:2 1:4 1:8 1:16 1:32 1:64 No mAb Dilution factor SUBSTITUTE SHEET (RULE 26) Mg/ml 0 CR8059 —| HAO CR8033 HAO l HAO SUBSTITUTE SHEET (RULE 26) A \ V B ' Uninfected Infected, no mAb infected, CR8033 Infected, CR8059 Budding virions in Virions not readily CR8059-treated Detected in CR8033 s Treated SEM samples Scale bars represent 1 |jm SUBSTITUTE SHEET (RULE 26) o o M SJ s s -J -c n H -c SJ s o ui a> o a> 0\ *3 O 15 mg/kg 5 mg/kg 1.7 mg/kg Vehicle — 15 mg/kg — 5 mg/kg — 1.7 mg/kg = e ~ 21 21 B/Florida/